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Executive summary
Inspired by unprecedented improvements in human health and development in recent 
decades, our world has embarked on a quest that only a generation ago would have been 
considered unreachable—achieving sustainable health and development for all. Improving 
the health and wellbeing of the world’s people is at the core of the Sustainable Development 
Goals (SDGs), reflected in targets that call for ending the epidemics of AIDS, tuberculosis, 
and malaria; achieving enormous improvements in maternal and child health; and tackling 
the growing burden of non-communicable diseases (NCDs). Attaining universal health 
coverage is the means by which these ambitious health targets are to be achieved.
Although on their face, the SDGs reflect an unprecedented level of global solidarity and 
resolve, the trends that increasingly define our world in 2018 are inconsistent with both the 
sentiments that underlie the SDGs and the ethos that generated such striking health and 
development gains in recent years. Democracy is in retreat, and in many countries the space 
for civil society is declining and the human rights environment deteriorating. Official 
development assistance for health has stalled, as an inward-looking nationalism has in many 
places supplanted recognition of the need for global collaboration to address shared 
challenges. The loss of momentum on global health ignores the urgent need to strengthen 
health systems to address the steady growth of NCDs, which now account for seven of ten 
deaths worldwide.
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Recent trends in the HIV response are especially concerning. Although the number of new 
HIV infections and AIDS-related deaths have markedly decreased since the epidemic 
peaked, little progress has been made in reducing new infections in the past decade. Without 
further reductions in HIV incidence, a resurgence of the epidemic is inevitable, as the largest 
ever generation of young people age into adolescence and adulthood. Yet where vigilance 
and renewed efforts are needed, there are disturbing indications that the world’s commitment 
is waning. Allowing the HIV epidemic to rebound would be catastrophic for the 
communities most affected by HIV and for the broader field of global health. If the world 
cannot follow through on HIV, which prompted such an extraordinary global mobilisation, 
hopes for achieving the ambitious health aims outlined in the SDGs will inevitably dim.
At this moment of uncertainty for the future of the HIV response and for global health 
generally, the International AIDS Society and The Lancet convened an international 
Commission of global experts and stakeholders to assess the future of the HIV response in 
the context of a more integrated approach to health. A central finding of the Commission is 
that the HIV epidemic is not on track to end and that existing tools are insufficient. Although 
antiretroviral therapy (ART) has transformed the HIV response by averting deaths, 
improving quality of life, and preventing new HIV infections, HIV treatment alone will not 
end the epidemic. The UNAIDS 90–90-90 approach must be accompanied by a similarly 
robust commitment to scaled-up primary HIV prevention and to the development of a 
preventive vaccine and a functional cure for HIV. Ironically, the diminishing energy on HIV 
is occurring at the moment when lessons learned during the HIV response could serve as 
pathfinders in the quest for sustainable health for all.
From its inception, the HIV response was a unique undertaking, apart from the broader 
health system. Although elements of a disease-specific approach will and should be retained, 
the future of the HIV response will also depend on finding opportunities for integrating HIV 
services more closely within health systems. Wholesale abandonment of vertical HIV 
funding would involve considerable risks, as the laser-like focus on a single disease accounts 
in large measure for the HIV response’s successes. Unique attributes that have defined the 
HIV response (including its multisectoral and inclusive approach, engagement of civil 
society, emphasis on equity and human rights, galvanisation of scientific innovation, and 
foundation of global collaboration and problem solving) must be preserved and 
mainstreamed across global health practice.
Whether to integrate HIV within broader health systems is not an either-or choice, and 
optimal paths will differ between settings, populations, and services. To be effective, more 
integrated approaches must yield improvements both to HIV-related and non-HIV-related 
health outcomes. In most cases, approaches to integration will and should be incremental, 
allowing learning by doing. To assess the health and financial benefits of such win-win 
scenarios, the Commission engaged modellers to examine different scenarios for incremental 
integration of HIV-related and non-HIV-related services. These include: models in South 
Africa and Kenya for screening of HIV alongside screening for diabetes, hypertension, and 
other NCDs; integration of HIV in reproductive health services in Nigeria; integrated 
management of HIV and sexually transmitted infections in India; and integration of harm 
reduction and overdose services and ART for people who use drugs in Russia. In each of 
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these scenarios, integrated approaches generated concrete improvements in HIV and broader 
health outcomes. With one exception (antiretroviral pre-exposure prophylaxis [PrEP] in 
India), integrated models were consistently found to be cost-effective.
The HIV community must make common cause with the global health field— to make 
universal health coverage a reality, to substantially increase the share of resources devoted to 
health, and to build worldwide recognition of health as key to progress across the breadth of 
the SDGs. The global health field must take a leading role in resisting the turn towards 
authoritarianism, xenophobia, and austerity with respect to essential public health 
investments. In a time of fragmentation and uncertainty, the global health field can aid in 
reminding all of us of our common humanity. Health systems must be designed to meet the 
needs of the people they serve, including having the capacity to address multiple health 
problems simultaneously. No one can be left behind in our efforts to achieve sustainable 
health. Recognising health as an investment, major new resources (from national 
governments, the international community, and the private sector, involving innovative 
financing mechanisms) must be mobilised to support stronger, sustainable, and people-
centred health systems.
Global health and HIV
The SDGs sharply elevate global health and development aspirations, contemplating a world 
that is far more prosperous, secure, healthy, and equitable, where human rights and dignity 
are universally respected, and where human development unfolds in a manner that preserves 
the natural environment. Yet, the 3 years that have passed since the SDGs were agreed have 
dimmed prospects for achieving many of these visionary aims. By contrast with the 
international solidarity, shared commitment, and increased investments that characterised the 
era of the Millennium Development Goals (MDGs), much of the world has, since 2015, 
turned inward and toward authoritarianism, repression, a diminished role for civil society, a 
policy of austerity for public investments, and suspicion of international cooperation. As a 
result of civil conflicts that have yet to elicit an appropriate international response, more 
people than ever have been forced from their homes and countries. At a time when the fruits 
of scientific advances are so evident, denial in many quarters of the role of humankind in the 
degradation of our environment threatens the very health and wellbeing of our planet and our 
civilisations.
Among the reasons why the world opted for such an ambitious agenda for the SDGs was the 
success of the HIV response. As a result of a worldwide mobilisation, the incidence of HIV 
infections peaked and began to decrease in all parts of the world, and AIDS-related mortality 
decreased from 1–9 million in 2005 to 1–0 million in 2016.1 The HIV response has not been 
an unalloyed story of achievement, as the world’s capacity to respond effectively to the 
epidemic has been undermined by 15 years of relative inaction in the epidemic’s early 
stages, an approach to epidemic management that has undervalued primary prevention, and 
the enduring stigma associated with HIV.
The broader global health community, facing both historic opportunities and profound 
challenges, could potentially benefit from lessons learned from the successes and failures of 
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the global HIV response. With its multisectoral and inclusive approach, mobilisation of 
political commitment, engagement of civil society at every level, emphasis on equity and 
human rights, galvanisation of scientific innovation, and foundation of global collaboration 
and problem solving, the HIV response has properly been cited as a model for the future of 
global health.2 The global health challenge remains immense, with millions of people in 
low-income and middle-income countries (LMICs) dying each year from causes that have 
either been largely eradicated or are decreasing in prevalence in high-income countries 
(figure 1).3 Whether the world is prepared to meet these challenges is unclear. Although the 
incidence of communicable, maternal, neonatal, and nutritional diseases have decreased 
worldwide since 1980,3 the most recent projections indicate that financial resources 
available for health programmes in LMICs are likely to fall far short of amounts needed to 
reach the health targets set forth in the SDGs.4 Persistent weaknesses of health systems 
undermine prospects for progress in addressing the full panoply of health challenges.
At the very moment when HIV could serve as a pathfinder for global health, there are signs 
that global commitment to build on the gains achieved against HIV thus far is waning. From 
2013 to 2016, international HIV assistance was reduced by roughly 20%, from almost US
$10 billion to US$8·1 billion.5
Relinquishing the fight against HIV before it is over would have disastrous consequences, 
both for people affected by HIV and for the broader global health community. Unless further 
investments are made to accelerate expansion of HIV prevention and treatment programmes, 
the HIV epidemic is likely to rebound and grow far more serious in the coming years, 
especially as the world’s largest-ever cohort of young people age into adolescence and 
young adulthood.6 Notwithstanding the enormous progress that has been made in the HIV 
response, HIV remains “the epidemic of our time”.7 In 2015–16, an estimated 36·7–38·8 
million people were living with HIV worldwide, including 1·9–2·5 million newly infected in 
2015.1,8 More than 35 million people have died of AIDS-related causes; 1·0 million of these 
deaths were in 2016.9 A refusal to follow through to achieve long-term control of the 
epidemic would merely repeat a longstanding pattern in global health, when failure to 
sustain a surge in global interest in combating particular health threats allows these 
epidemics to return in force. The history of malaria elimination efforts is a case in point, as 
the failure to sustain malaria-related control programmes, funding, and research investments 
led to an abandonment of the global malaria elimination campaign in 1969 and subsequent 
increases in the global malaria burden.10 At a moment when the means to improve human 
health are greater than ever, allowing a resurgence of HIV through neglect and apathy could 
deal a blow from which the broader cause of global health could need decades to recover.
The relationship between the HIV response and the broader global health field is 
multilayered and bidirectional. Even as the HIV response offers important lessons from 
which global health can learn, it is also clear that controlling the HIV epidemic will depend 
in large measure on the broader global health and development fields. However, the 
exceptionalist approach to the HIV epidemic, in which the HIV response has often unfolded 
as a vertical undertaking, distinct from other health programmes, has achieved historic 
results and should not be jettisoned lightly.
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Both the HIV response and the broader global health field share a commitment to the 
development of health systems that are capable of addressing several health challenges at the 
same time. In many settings, robust, if still flawed, service systems have been developed for 
certain populations (eg, pregnant women, children) or for priority health conditions (eg, 
maternal and child health, HIV, and other communicable diseases). However, health systems 
as a whole are largely unprepared for providing care that is holistic, universal, and well 
coordinated. In the still-early years of the SDG era, the gap between reality and the vision of 
sustainable health remains gaping.
In the midst of uncertainty about the long-term feasibility of an exceptionalist HIV approach 
and the prospects for achieving the lofty health targets in the SDGs, the International AIDS 
Society (IAS)-Lancet Commission on the Future of Global Health and the HIV Response 
was established in 2016 to critically examine future prospects for global health and the HIV 
response. The Commission was tasked with assessing the future of the HIV response in a 
more integrated global health and development agenda, with the aim of advising how best to 
achieve global control of the HIV pandemic in an era in which health and development 
priorities are proliferating. The Commission studied the history of the HIV response to 
discern how experience in responding to HIV might inform and strengthen global health 
more broadly. Modelling exercises were undertaken to assess the effect of various 
approaches to improve integration of HIV and non-HIV-related services. The most salient 
threats to global health and to the goal of universal health coverage were identified.
With this report, we summarise the findings of the Commission, and we seek to articulate a 
vision for the future of the HIV response and global health that builds common cause across 
health and development movements and sectors. Rather than despair over the trends and 
patterns of the past several years, we must instead look to the extraordinary achievements of 
the past two decades to embolden us and reinforce our resolve to rejuvenate the HIV 
response and strengthen the broader cause of global health. By taking on board the lessons 
of the HIV response, the global health field can be made fit for the purpose of realising the 
vision of sustainable health for all. Global health can serve as a driving force to repudiate 
and discredit the continuing retreat from international solidarity, human rights, reason, 
scientific evidence, and open societies. Global health can serve as a pioneer in a re-
engineering of the development project, from one based on charity from the high-income 
countries to one that tackles the central determinants of global health inequities. Just as the 
HIV response has demonstrated that global problems demand global solutions, the future 
health and wellbeing of our planet relies on us to recognise, celebrate, and build on our 
common humanity.
With respect to the flagging response to HIV, the Commission hopes that this report serves 
as a wake-up call. Without a thorough rejuvenation of the HIV response and a change of 
course, we are likely to see a resurgence of the epidemic. After such history-making 
successes from unprecedented global solidarity and collaboration, the world can and must do 
better.
To realise the vision of sustainable health for all, we must ensure that health systems are 
equipped to bring communicable diseases under control and to respond effectively to the 
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growing burden of NCDs. A focused response and categorical HIV funding will remain 
crucial to avoid a resurgence of HIV and to bring the global pandemic under control. 
However, immediate and incremental steps are needed to strategically integrate HIV services 
into co-located primary care platforms and toward the longer-term goal of creating fully 
integrated, co-located, and patient-centred health-service systems.
Global Health in 2018: new ambitions and growing threats
The Agenda for Sustainable Development envisages “a world free from poverty, hunger, 
disease and want, where all life can thrive.”11 SDG 3 calls for concerted action to ensure 
healthy lives and promote wellbeing for all at all ages.11 SDG 3 also calls for ending the 
epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases; eliminating 
preventable deaths in children younger than 5 years; and reducing by a third the number of 
deaths from NCDs.11 Under the Agenda for Sustainable Development, universal health 
coverage serves as the primary vehicle for continuing and fully leveraging the momentum on 
health.11
The health targets of SDG 3 build on historic gains made under the MDGs (panel 1).12 The 
health gains during the MDG era coincided with, and were enabled by, advances across the 
broader development agenda. Whereas nearly half of the population in LMICs lived on less 
than $1·25 per day in 1990, this proportion had fallen to 14% by 2015.12 Primary school 
attendance worldwide increased between 2000 and 2015, and differences in secondary 
school attendance between boys and girls diminished or disappeared altogether in some 
regions.12
Decreasing prominence of health on the global political stage
Whereas health occupied three of the eight MDGs, health is specifically addressed in only 
one of 17 SDGs and ten of 169 SDG targets. Effective measures to improve global health 
outcomes draw on principles of international solidarity and shared responsibility, 
recognising that all of us, irrespective of where we live, have a stake in improving the health 
of our planet and its people. Yet growing hostility towards globalisation, which has become 
especially pronounced in many countries that have long served as global health donors, 
poses a potential threat to all forms of international and multilateral cooperation, including 
global collaboration to address health and development challenges. As threats to global 
solidarity have intensified, stresses on such multilateral institutions as the European Union 
(EU) have become more apparent.
Substantial additional health investments will be necessary to achieve the SDG 3 targets. Yet 
prospects for mobilising such sums appear in doubt as global assistance for health has 
flattened since 2010.13 Although domestic investments in health by LMICs have generally 
increased since 2000,14 these investments frequently fall short of leaders’ stated ambitions. 
In the Abuja Declaration of 2001, African heads of state committed to allocate 15% of 
government budget to health, yet most countries are not reaching this agreed benchmark.15 
Economic growth in LMICs (estimated at 3·9% in 201616), if sustained, has the potential to 
expand the fiscal space for investments in health if sufficient political commitment exists. 
However, most low-income countries will for the foreseeable future lack the capacity to fully 
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finance health and development initiatives on their own, underscoring the continued need for 
robust and sustained international assistance.17
Weak and dysfunctional health systems and the future of global health
Health systems in much of the world appear unprepared to realise the vision of sustainable 
health for all. As recently as 2013, 37 of 49 countries in Africa did not have a single medical 
laboratory that satisfied international quality assurance standards.18 In 2013, the number of 
health workers needed to provide essential health services fell 17·4 million short of the 
number needed, with the most severe shortages occurring in Africa and southeast Asia.19 In 
Africa, health worker shortages are expected to worsen in the coming years.19
Weak and overburdened health systems that are already struggling to provide basic services 
will confront vastly more serious stresses in the coming years. The global population is 
projected to grow from 7·6 billion people in 2017, to 9 8 billion people by 2050, with the 
sharpest increase set to occur in Africa, where the population will roughly triple in size.20 
Many health systems are unprepared to carry through on the SDG 3 target of reducing NCD-
associated premature mortality by a third. Although LMICs are home to 70% of global 
cancer deaths, they account for only 5% of cancer spending world-wide.21 Some countries in 
Africa have no clinical oncologists, whereas India reportedly had only 29 treatment centres 
to manage cancer for more than 1 billion people in 2010.22
Confronting the inherent inequities of the international order
The narrowing of economic disparities between rich and poor countries represents one of the 
signal achievements of our era, but yawning inequities in access to resources between 
countries and regions persist. In 2016, the per-capita gross domestic product (GDP) in North 
America was more than 34 times higher than in south Asia or sub-Saharan Africa and nearly 
92 times higher than in low-income countries generally.23 These extraordinary disparities in 
access to the fruits of the global economy are inevitably reflected in health outcomes 
because lower socioeconomic status is closely correlated with poorer health.24
In addition to differences between countries, persistent social and economic inequalities 
within countries increase vulnerability to disease and diminish service access. In diverse 
countries, lower-income households consistently have poorer access to health care than the 
more affluent and experience comparatively greater morbidity and mortality.25
Existing global health mechanisms and practices fail to ensure ready, equitable access to 
international public goods such as medicines and diagnostics. Although the 2001 Doha 
Declaration on TRIPS and Public Health recognised the flexibility of countries under 
international law to obtain access to essential medicines, the global community has yet to 
find a workable balance between trade and the right to health. Unfortunately, the HIV 
response, which achieved a 99% reduction in the annual cost of first-line ART between 2000 
and 2015, largely remains an outlier with respect to medicines access in resource-limited 
settings. Affordable diagnostic tools are also often in short supply. Nearly half of African 
countries have no cancer radiotherapy services, leaving four of five Africans without access 
to radiotherapy.26
Bekker et al. Page 10
Lancet. Author manuscript; available in PMC 2019 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The 2014 Ebola outbreak in west Africa underscored the ongoing crisis of global health 
governance.27 Although the International Health Regulations were designed in part to 
discourage restrictive and coercive responses to health emergencies, nearly a quarter of the 
WHO member states imposed restrictions on trade and travel in response to the Ebola 
outbreak.28 WHO, a cornerstone for global health governance, remains chronically 
underfunded and hobbled by a decentralised structure, which often inhibits rapid and 
effective responses to emerging health crises.29
Deteriorating environment for human rights, sound governance, and global cooperation
The underlying political and social environment is shifting in ways that are inimical to good 
health and to the development of sound and sustainable health systems. After years in which 
the proportion of the world’s people living in free and democratic societies increased, 
freedom is now in retreat, with one global freedom index reporting the 11th consecutive year 
of decline in 2017.30 Accompanying this democratic retreat is growing official hostility 
toward civil society in many countries.30
The increase in authoritarianism and the decrease in adherence to democratic norms also risk 
normalising human rights violations and degrading universal human rights commitments. 
The global retreat on human rights has exacted an especially heavy toll on migrants and 
other disenfranchised groups. In 2015, the global population of displaced people was greater 
than ever (21 million people) as raging conflicts in Syria and elsewhere have compelled 
millions of people to flee their homeland.31 More recently, government-sanctioned violence 
against the Rohingya minority in Myanmar has caused hundreds of thousands of people to 
seek sanctuary in neighbouring countries.
Discriminatory practices within health systems, which frequently mirror prejudices prevalent 
in the broader population, prevent many from accessing the most basic health services. 
Migrants, indigenous populations, and ethnic minorities often encounter hostility from 
health providers (including, in the case of migrants, formalized exclusion of non-citizens 
from health-care services).25 Lesbian, gay, bisexual, and transgender people worldwide 
experience considerable difficulties in accessing good quality and non-judgmental health 
services.32
Threats to planetary health
While political, social, and economic patterns threaten the foundation of global health, 
continued deterioration of the physical environment potentially poses an existential threat to 
the planet.33 The planet is warming because of human activity, and failure to take swift 
action to arrest or slow the growing concentration of manmade greenhouse gases is projected 
to lead to further devastating increases in temperature in the coming decades. Threatening 
the very habitability of our planet, these trends will have powerful effects on health, 
affecting food production, susceptibility to heat-related illnesses and natural disasters, and 
patterns for vector-borne and water-borne diseases.
The world’s response to climate change in many respects serves as a fundamental test case 
for international action to address shared threats. In this respect, recent trends are not 
promising. In 2018, authoritative reports on climate trends indicated that no developed 
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country is on track to meet its pledges under the Paris Agreement and that current warming 
trends suggest that the global temperature will rise in coming decades well beyond the 
maximum threshold set by the Paris Agreement.34
Towards sustainable health for all: a status report
As a result of remarkable increases in health spending,35 the much healthier since 1990. 
Under-5 mortality decreased from 90 deaths per 1000 livebirths in 1990, to 43 deaths per 
1000 livebirths in 2015, the proportion of children younger than 5 years who are 
underweight decreased from 25% to 14%, and maternal mortality decreased by 45% 
worldwide.12 Adolescent mortality is estimated to have decreased by about 17% since 2000. 
Notable reductions in the incidence of new infections and deaths associated with HIV, 
tuberculosis, and malaria between 2000 and 2015 led the UN to declare that these epidemics 
had been halted and reversed.12 Globally, life expectancy increased faster in 2000–15 than in 
half a century, increasing on average a full 5 years. The greatest increase in life expectancy 
occurred in Africa, which had previously seen sharp reductions in life expectancy as a result 
of the HIV epidemic (figure 2). With three of the eight MDGs specifically focused on health, 
the MDG agenda catalysed a remarkable increase in official development assistance for 
health.
An enormous gap persists between current reality and the vision of sustainable health for all. 
Although numerous LMICs have made important strides in expanding health coverage,36 
400 million people do not have access to essential health services, and 6% of people in 
LMICs are impoverished or pushed deeper into poverty by household medical expenses.37
More than 15 000 children younger than 5 years die every day, largely from preventable 
communicable diseases and malnutrition.38 45% of childhood deaths are associated with 
undernutrition, 80% are associated with low birthweight, and NCDs are increasing as a 
major cause of death in children.39 In 2015, 1·2 million adolescents died, largely from 
preventable causes.40 Adolescents are at high risk of sexually transmitted infections 
(including HIV41), unintended pregnancy, unmet contraceptive need, and contraceptive 
failure.42
NCDs (eg, cancers, cardiovascular disease, hypertension, and diabetes) account for 70% of 
deaths worldwide, and more than 75% of NCD-related deaths occur in LMICs.43 In the 
future, LMICs will account for up to 80% of the anticipated global increase in cancer cases 
and deaths.44 NCDs are projected to exact economic costs of $47 trillion in the next two 
decades,45 and progress in combatting NCDs will affect the world’s ability to attain at least 
nine of the 17 SDGs.46
While the world mobilises to address NCDs as the primary driver of mortality and disability, 
the global community must follow through on its commitments to make communicable 
diseases a thing of the past. Tuberculosis, for example, is the leading cause of death by 
single infectious agents, the ninth leading cause of death overall (accounting for 1·7 million 
deaths in 201638), and the leading cause of death in people living with HIV.47 Africa 
accounts for roughly 80% of all cases of and death from combined HIV and tuberculosis. 
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Unlike HIV, tuberculosis is a curable infection. Nearly half of the world’s population is at 
risk for malaria, and no meaningful progress in reducing malaria cases and deaths was seen 
in 2016.48 Likewise, the challenge of addressing viral hepatitis remains considerable (figure 
3). An estimated 71 million people worldwide have chronic hepatitis C virus (HCV) 
infection, and 2·7 million of these people have HIV infection.51 An estimated 1·34 million 
people die from viral hepatitis each year, and this includes an estimated 399 000 deaths 
related to HCV infection.51
Alcohol and drug use disorders are associated with extensive morbidity, disability, and 
mortality52 and are also closely linked with HIV transmission through the sharing of 
syringes and the effects of specific drugs (eg, amphetamines) on condom use and sexual 
HIV transmission.53 In 2016, mental health disorders accounted for nearly 16% of years 
lived with disability worldwide.52
HIV and global health: what have we learned, and where do we go from 
here?
The global HIV response serves as one of the most inspiring undertakings in the history of 
global health. The escalating toll of AIDS across the world in the 1980s and 1990s, 
especially in sub-Saharan Africa, resulted in “the single greatest reversal in human 
development” in history.54 However, a genuinely multi-sectoral and multidimensional global 
mobilization uniting and synergising a diverse set of actors from all across the world 
achieved what some considered unattainable: halting and beginning to reverse the epidemic.
55
 These health advances have had profoundly positive effects on households, communities, 
and societies. In South Africa, home to nearly one in five people living with HIV, sharply 
reduced AIDS-related mortality stemming from a remarkable expansion of HIV treatment 
services caused average life expectancy to increase from 52 years to 61 years in less than a 
decade.56
An unprecedented expansion of access to ART
The greatest achievement of the HIV response to date has been the unprecedented global 
expansion of access to ART. Although only 680 000 people were receiving ART in 2000 
(most of them in high-income countries), by June 2017, this number had risen to 20·9 
million people (18·4 million–21·7 million), or 57% of all people living with HIV worldwide.
57
 In 2016, an estimated 1·6 million deaths were averted worldwide as a result of ART.1
The history of ART and its effect on the global HIV epidemic is one of multidisciplinary 
collaboration, continual improvements in the quality and durability of treatment regimens, 
ever-increasing aspirations for service coverage, and passionate advocacy to overcome the 
resistance that HIV treatment expansion elicited. Public and private sector researchers 
combined to generate the therapies capable of halting viral replication; civil society 
advocacy and competition from and within the generic pharmaceutical industry coalesced to 
produce marked reductions in the prices of ART; robust funding, primarily at the outset from 
international donors, enabled rapid introduction and expansion of treatment programmes; 
and programme planners and implementers (as well as affected communities) have helped to 
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improve the efficiency and effectiveness of HIV treatment service delivery. As the scientific 
evidence expanded, normative guidance on HIV treatment evolved, and in 2015, WHO 
recommended the initiation of ART for all people living with HIV, irrespective of disease 
stage, both for clinical benefit to the individual living with HIV and for the prevention 
benefits of successful viral suppression on onward transmission.58
Substantial scientific advances have also been achieved in primary HIV prevention. 
Principally due to implementation of ART for pregnant women and other measures to 
prevent vertical HIV transmission, the number of children newly infected with HIV 
decreased from 470 000 children in 2002, to 160 000 children in 2016.1 Since results of 
clinical trials more than a decade ago showed that medical male circumcision reduces the 
risk of female-to-male sexual HIV transmission by about 60%,59 nearly 15 million men in 
sub-Saharan Africa have been circumcised.60 PrEP has substantial HIV prevention efficacy,
61
 and cash transfers might reduce young people’s HIV risk behaviours or the odds of 
acquiring HIV, or both.62
The future of HIV: an unfinished agenda with an uncertain outcome
The fight against HIV is far from over. In eastern Europe and central Asia, the incidence of 
new HIV infections increased by 60% between 2010 and 2016,5 and the incidence is also 
trending upwards in populous countries such as Philippines and Ghana.1 Progress in 
reducing new HIV infections in adults has largely stalled worldwide. Although UNAIDS 
estimates that new HIV infections in adults decreased by a modest 11% between 2010 and 
2016,5 the Global Burden of Disease Study 2015 investigators found no meaningful decrease 
in new HIV infections in the previous decade.8 The coming demographic wave, as children 
become adolescents and young adults, threatens major expansions of the epidemic. In 2016, 
43% of the population in low-income countries, 43% of the population in all of sub-Saharan 
Africa (excluding high-income countries), and 31% of the population in lower-middle 
income countries were younger than 15 years.63 In a recent modelling study, the failure to 
build on existing prevention and treatment coverage gains was found to result in a rebound 
of the HIV epidemic in the coming years.64
The 90–90-90 approach: its promise and its limitations
As part of the SDGs, UN member states have pledged to end the AIDS epidemic as a public 
health threat by 2030, which has been defined as reducing the number of new HIV infections 
and AIDS-related deaths by 90% relative to 2010. The cornerstone of this global 
undertaking is the UNAIDS 90–90-90 approach, which follows that by 2020, 90% of all 
people living with HIV will know their HIV status, 90% of people with an HIV diagnosis 
will receive ART, and 90% of people receiving ART will achieve viral suppression.65 The 
90–90-90 approach is grounded in the considerable evidence that ART sharply reduces the 
risk of HIV transmission.66 Within the Fast-Track strategy proposed by UNAIDS to reduce 
the incidence of new HIV infections to less than 200 000 annually by 2030, UNAIDS 
estimates that scaled-up ART will account for 60% of HIV infections averted during this 
period.64
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However, it is increasingly clear that the 90–90-90 approach on its own will be inadequate to 
end the epidemic. Even as ART coverage has steadily increased and as the HIV response has 
adopted an almost singular focus on HIV treatment expansion, the rate at which the 
incidence of new HIV infections is decreasing remains far too slow to achieve epidemic 
control. A case in point is Botswana, which might already have achieved the 90–90-90 
target,67 but the decrease in new HIV infections is far too modest to end the country’s 
epidemic.1
Outcomes across the HIV treatment continuum in eastern and southern Africa, Latin 
America, and high-income countries are cause for optimism that the 90–90-90 target might 
be achieved by 2020 in these settings (figure 4). However, in other regions, the proportion of 
people living with HIV who had suppressed virus in 2016 was far off the pace for the 73% 
target viral suppression benchmark for 2020 under the 90–90-90 approach (viral suppression 
was achieved for 34% of people with HIV in the Caribbean, 25% in west and central Africa, 
22% in eastern Europe and central Asia, and 16% in the Middle East and north Africa).1 
Ensuring widespread viral suppression is also a challenge in many high-income countries 
such as the USA, where only 49% of people with HIV were virally suppressed in 2014.68
The prevention benefits of expanded ART would be substantially enhanced by a similarly 
vigorous scale-up of other strategic prevention interventions. In Uganda, the combination of 
steady expansion in ART coverage, a near-doubling of the rate with which HIV viral 
suppression is achieved, and roll-out of medical male circumcision was associated with a 
42% reduction in HIV incidence in 10 years.69 In cities in high-income countries, the 
prioritised roll-out of PrEP as a complement to the test-and-treat approach has contributed to 
sharp decreases in the incidence of new HIV infections, especially in gay and bisexual men.
70,71
 Although the so-called combination prevention approach has long been recommended 
as the optimal means to reduce the risk of new HIV infections, the approach has seldom 
been implemented at scale because national HIV responses have increasingly come to be 
dominated by an overwhelming emphasis on HIV treatment. Less than one in five people at 
risk of HIV acquisition have access to prevention programmes because of chronic 
underfunding of HIV prevention.6
An alternative future for the HIV epidemic: persistent settings and communities with heavy 
HIV burdens
Far from putting the world on course to vanquish AIDS, existing approaches are leaving 
numerous populations behind. In sub-Saharan Africa, young people and men of all ages 
consistently have suboptimal outcomes along the HIV treatment continuum.5 Various 
marginalized populations at increased risk of HIV infection, including gay and bisexual 
men, people who inject drugs, sex workers, transgender people, and the sex partners of 
people in these groups, accounted for 44% of new HIV infections worldwide (80% of new 
infections outside sub-Saharan Africa).5
Contrary to optimistic expectations of ending AIDS, these trends point toward the likelihood 
of a much more concerning scenario. Athough the desired benefits of population-level viral 
suppression could be realised in settings and populations where access to HIV testing and 
treatment services is widespread, those people living in countries or belonging to 
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marginalised populations in which services are difficult or impossible to obtain will remain 
highly vulnerable to HIV acquisition.
Already, evidence suggests that the epidemic is sustained in substantial high-prevalence and 
high-incidence geographical areas in large measure by the inability of service systems to 
reach and engage specific populations. For example, even as the incidence of HIV infections 
in the USA have decreased overall since 2008,72 black gay and bisexual men now have a 
50% lifetime chance of acquiring HIV (figure 5).73 Rates of viral suppression in people 
living with HIV in the USA have steadily improved,74 but black gay and bisexual men living 
with HIV are markedly less likely than other people living with HIV to receive ART, remain 
engaged in care, and achieve viral suppression.75 Major pockets of endemic HIV are also 
apparent in Russia, where HIV infections are heavily concentrated in six subnational regions 
(referred to as Federal Subjects) in eastern and western Siberia, along principal overland 
heroin and opium trafficking routes out of Afghanistan. In the case of people who inject 
drugs, in Russia and elsewhere, access to prevention and treatment services is extremely 
limited.76 A similar clustering of susceptibility to HIV is apparent in the KwaZulu-Natal 
province of South Africa, where adolescent girls and women younger than 25 years are 
roughly three times more likely than men younger than 25 years to be living with HIV.77
The persistence of large, high-prevalence, and high-incidence areas in the midst of 
epidemics that are large and small, decreasing and increasing, is a global phenomenon. 
Compared with the population as a whole, gay men and other men who have sex with men 
(MSM), people who inject drugs, sex workers, and transgender women are 19 times,78 13·5 
times,79 22 times,80 and 49 times,81 more likely to be living with HIV, respectively. Yet 
although these marginalised populations have a disproportionate and growing HIV burden, 
they are often the groups least likely to obtain access to HIV prevention, treatment, and care 
services.78
With the failure of existing service approaches to address persistent susceptibility or to reach 
those people who are in greatest need, it is clear that new and scaled-up service delivery and 
community engagement strategies will be needed. The transmission-preventing potential of 
scaled-up ART must be matched with an equally strong reduction in the risk of HIV 
acquisition and transmission.7,82 And programmes for the delivery of prevention and 
treatment services must be coupled with renewed efforts to address the social and structural 
factors that increase risk and susceptibility and diminish utilisation of essential services.
Activism and the future of the HIV response
Grassroots political activists have had a defining role in the HIV response. In the epidemic’s 
early years, gay communities in several countries mobilised to resist the imposition of 
coercive measures in what was then a new and frightening epidemic. Across the world, 
chapters of the AIDS Coalition to Unleash Power (ACT UP) marched in the streets and 
infiltrated decision making bodies to demand greater investments in HIV research and 
expedited, people-centred approaches to the evaluation and approval of new medicines. In 
South Africa, activism by Treatment Action Campaign and other groups led to dramatic 
changes in national HIV policies, which have reverberated around the world. In every 
region, activists have emerged to challenge high prices for HIV treatments and to insist on 
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approaches to intellectual property that take into account the needs of people with life-
threatening diseases.
Today, inclusion of civil society and people living with HIV is standard practice of many 
HIV-related decision making bodies. Non-governmental representatives, including from 
organisations and networks of people living with HIV, are now routinely involved in national 
HIV-related advisory bodies. Vigorous activism persists in many countries and regions. 
However, as the incidence of HIV infections and AIDS-related mortality have decreased, 
and as funding for civil society activities has diminished, so have the magnitude and 
intensity of AIDS activism. In particular, the kind of cohesive activist voice that united the 
global north and south and laid the foundation for the HIV treatment revolution is no longer 
evident. In some cases, experiences in the HIV response have led some activists to 
concentrate more on broader health and human rights issues. For some, a focus on service 
delivery in their own communities has taken the place of activism for systemic change.
Standard inclusion of civil society in national and global bodies is one of the great 
achievements of the HIV response and one of its defining features, yet the voices of 
grassroots activists are at risk of being silenced or muffled. As a class of international and 
non-governmental HIV professionals has developed, questions have emerged about a 
potential disconnect between civil society spokespeople at the global level and those 
working in communities. The inclusion of civil society in decision-making bodies, 
especially at the global level, is often more tokenistic than substantive.
How to rejuvenate and empower a new wave of activism on HIV remains a topic of 
considerable discussion and debate within the HIV community (figure 6). What is clear is 
that the loss of a strong activist presence diminishes both the accountability of the HIV 
response and the likelihood that our policies, programmes, and approaches will respond to 
the communities being left behind. Few advocacy community equivalents to HIV exist in 
other domains of global health. Infusing the broader global health field with the grassroots 
energy and leadership that has defined the HIV response could revolutionise global health 
and elevate it on the global political agenda, but a key first step towards this end is to 
reinvigorate HIV activism.
The future of HIV exceptionalism
From the earliest recognition of the epidemic in the early 1980s, the HIV response adopted 
an exceptionalist approach. Rather than look to often-overburdened health systems to 
manage HIV as one of many health problems, specific vertical funding mechanisms and 
frequently disease-specific service delivery channels were established to respond to the 
global emergency. In 2000–01, diverse global stakeholders spearheaded the creation of the 
Global Fund to Fight AIDS, Tuberculosis and Malaria, which, by the end of 2016, had 
allocated more than $17 billion for HIV programmes in more than 100 countries, while also 
providing much needed support to chronically neglected tuberculosis and malaria.83 Created 
in 2003, the US President’s Emergency Plan for AIDS Relief (PEPFAR) is the largest 
bilateral health programme ever devoted to a single disease. The UN also took a distinctly 
unorthodox approach to HIV, vesting UN leadership on the epidemic, not with the 
Bekker et al. Page 17
Lancet. Author manuscript; available in PMC 2019 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
designated health agency WHO, but in the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), a multidisciplinary and cosponsored programme.84
Whether such an exceptionalist approach will remain feasible is unclear. Overall investments 
in the HIV response, taking into account both domestic and international sources, has 
remained relatively flat in recent years, at about $19.1 billion, roughly $7 billion short of the 
amounts needed to achieve 90–90-90 and the broader UNAIDS Fast-Track strategy.5 In 
2016, total resources for HIV programmes actually decreased by 7%.85 In the midst of 
growing insecurity and disorder in the regions that have historically led in mobilising 
international financing for the HIV response (namely, North America and Europe), HIV 
seems less frightening than in earlier times. African leadership in the HIV response, so 
crucial to success under the MDGs, is also less visible. In a globalised world where attention 
spans are limited, the temptation to pretend that HIV is a problem that has been solved has 
proven to be powerful.
As the HIV response grapples with an uncertain future and works to identify optimal 
strategies for sustainability, it faces a pivotal challenge in defining, for the long-term, its 
relationship to the global health field. Appropriately integrating HIV within broader health 
systems will probably be essential to achieve ambitious global HIV aims, sustain treatment 
access in decades to come, and spread costs associated with controlling the epidemic. 
However, there are genuine risks to wholesale relinquishment of the exceptionalist approach 
to HIV. Notwithstanding the many criticisms of vertical health programmes, there is little 
dispute that HIV exceptionalism has worked, mobilising extraordinary new financial, 
technical, and human resources, uniting diverse stakeholders, focusing global attention on 
concrete results, driving and benefiting from scientific innovation, and engaging 
communities in far-reaching ways. Abandonment of an approach that has been 
groundbreaking in its success should not be done without a rigorous interrogation of the 
risks and benefits of mainstreaming the HIV response into national health systems.
Heeding the lessons of the HIV response
Even as the HIV response will inevitably depend on health and social systems to achieve its 
ambitious global target for 2030, lessons from the HIV response are also instructive for the 
future of global health. The UNAIDS-Lancet Commission on Defeating AIDS—Advancing 
Global Health in 2015 outlined the salient attributes of the HIV response that have 
contributed to its success and that should inform broader global health efforts. These include 
the sustained leadership of civil society and people living with HIV, the multistakeholder 
nature of the response, the extraordinary degree of political leadership for the fight against 
HIV, the centrality of human rights, gender equity, and social justice to the response, and a 
commitment to global and local-level accountability and transparency.6 Similarly pivotal has 
been the close link between scientific research and efforts to strengthen HIV programmatic 
efforts.
An emphasis on innovation has typified the HIV response from its earliest days and is in 
large measure responsible for bringing the world to the point where HIV as a medical 
problem can be effectively managed. Continuing research investments have made possible 
first-line HIV treatment regimens that are more durable, more tolerable, and less expensive 
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than the regimens that have already saved millions of lives. Additional innovations that are 
anticipated in the coming years, including long-acting antiretroviral regimens for both HIV 
treatment and PrEP, are among the reasons for optimism that even greater progress against 
HIV is achievable in the coming years, including the ultimate goals of a preventive vaccine 
and a functional cure for HIV.
Infusing the HIV response with a renewed energy and sense of purpose will be challenging, 
but the future health and wellbeing of countless millions of people require that we meet this 
challenge. Decision makers must be made aware of the profound and indisputable 
humanitarian and economic stakes at play in the future of the HIV epidemic. While fully 
acknowledging the daunting challenges we face, the HIV community must reinvigorate itself 
and embrace the scientist-activist zeal that yielded such historic achievements.
Opportunities for integration and synergy in the global health and HIV 
responses
Linking global health and HIV responses more closely and integrally across health 
programmes and practice is hardly a new idea. Experience in integrating HIV in broader 
health systems underscores both the benefits and potential risks associated with a more 
integrated and less exceptionalist approach to HIV, illustrates the challenges confronting 
greater linkage and integration, and highlights potentially valuable opportunities to rethink 
further how the HIV response fits within the broader global health enterprise. This 
experience further shows that the options for future programmatic approaches to HIV are not 
confined to a binary choice between exceptionalism or wholesale integration, but rather that 
several opportunities exist in the immediate-term for more incremental integration and for 
learning by doing. In all cases, steps toward integration should be undertaken thoughtfully, 
retaining the key principles that have defined the HIV response.
People and communities
To advance the SDGs’ goal of leaving no one behind and addressing the needs of the most 
susceptible first, innovative and rights-based approaches are needed to realise the vision of 
sustainable health for all. The particular health needs of different populations, outlined here, 
illustrate diverse ways in which the HIV response and the global health field can benefit and 
learn from each other.
Children’s health: ensuring that every child has the best chance at healthy 
adulthood—Comparatively well funded and vertical disease programmes have had a clear 
effect on child health. Childhood vaccination programmes, including programmes supported 
by G AVI, the Vaccine Alliance, have generated exceptionally high and increasing rates 
ofimmunisation.39 Between 2000 and 2014, measles vaccination is estimated to have saved 
17·1 million lives.86 Between 2010 to 2015, the mortality from malaria in children younger 
than 5 years decreased by 35%87 because of dramatic increases in the coverage of key 
malaria interventions.39
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The HIV response illustrates both the potential of focused global action to improve the 
health of children as well as the persistent failures of health systems to address children’s 
needs. As the proportion of pregnant women living with HIV who receive antiretroviral 
medicines has increased, the incidence of new HIV infections in children has sharply 
decreased. In 2016, the 160 000 new HIV infections in children represented a 47% decrease 
since 2010, and a 66% decrease since 2005.1
By contrast, little progress has been made with respect to integrated interventions that rely 
on regular contacts with the health system. Comparing utilisation data for 2000–08 with that 
of 2009–14, met demand for family planning services increased only modestly, from 54% to 
64%, the proportion of pregnant women who visited antenatal care at least four times 
increased only from 50% to 56%, the share of births with a skilled attendant increased only 
incrementally, from 55% to 65%, and similarly modest increases (less than 10%) were 
reported for exclusive breastfeeding, oral rehydration therapy, and care-seeking for 
pneumonia.39 Shortcomings in health systems that undermine health outcomes for children 
include weak laboratory systems, inadequate systems for monitoring mother-child pairs 
from antenatal to paediatric care settings, fragmented service delivery systems that invite 
discontinuity of care, and frequent drug stock-outs.
These deficiencies in health systems are evident with respect to HIV treatment for children. 
HIV treatment coverage in children (46% as of June, 2017) remains far lower than in adults 
(58%), resulting in notably higher morbidity and mortality in children than in adults.1 
Although children accounted for 6% of all people living with HIV worldwide in 2016, they 
made up 12% of all AIDS-related deaths.1 The persistent coverage gap between children and 
adults has long been excused by complexities associated with diagnosing and treating HIV 
in children, including the need for virological testing to confirm HIV infection in children 
and the historic shortage of child-appropriate antiretroviral reformulations. However, as a 
result of technological advances in recent years, the means to address these complexities 
now include point-of-care early infant diagnostic testing platforms, innovative methods to 
reduce turnaround times for standard virological testing by remote central laboratories, and 
striking progress in optimising treatment options for children.
Effectively integrating service delivery for children will meet children’s health needs in a 
holistic manner and provide co-located services that are effective, efficient, and of good 
quality. Health-service integration for children spans not only the levels of care (eg, 
community, primary, and referral) but also the child’s life (pre-pregnancy to childhood). The 
Global Action Plan for the Prevention and Control of Pneumonia is a valuable approach to 
service integration, providing a framework for coordinated and integrated actions to improve 
feeding and nutrition for infants and young children, access to safe drinking water and 
sanitation, hand washing with soap, reduction in indoor air pollution, immunisation, HIV 
prevention, and treatment of pneumonia and diarrhoea.88
Adolescent health—Health risks are especially acute for adolescent girls (figure 7). The 
risk of new HIV infections in women living in high-burden countries in sub-Saharan Africa 
peaks at age 15–24 years, about 10 years earlier than in their male peers, and AIDS persists 
as the fourth leading cause of death in adolescent girls and young women in sub-Saharan 
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Africa.89 The disproportionate health burden in adolescent girls stems from a confluence of 
factors, including the persistently low socioeconomic status of women in many societies, 
lack of educational and economic opportunities, and sharply limited access to family 
planning and adolescent-friendly health services.
One in four women worldwide become married before age 19 years, and 6% of women are 
married before age 15 years.90 Early marriage is linked with lower nutritional status, lower 
educational attainment, increased mortality for women,91 increased risk of HIV acquisition,
92
 intimate partner violence,93 and reduced health, nutritional status, and socioeconomic 
outcomes for their children.91
Particular risks are experienced by the estimated 21 million girls aged 15–19 years and the 2 
million girls younger than 15 years who give birth each year.94 Pregnancy during 
adolescence increases the risk of complications, and childbirth is the leading cause of death 
in girls aged 15–19 years.91 Giving birth during adolescence also increases health risks for 
newborn children, including low birthweight, preterm delivery, and poor long-term 
developmental outcomes.95 Minimising health risks for adolescent girls, including but not 
limited to HIV infection, will rely on an unprecedented, well resourced, and multisectoral 
effort. Keeping girls in school, through cash transfers and other strategies, is an overriding 
priority.
The HIV response has galvanised interdisciplinary work to clarify young people’s reasons 
for engaging in unprotected sex and effective means to reduce sexual risks. Data from 
extensive research have conclusively shown that abstinence is a failed strategy for HIV 
prevention.96 Effective prevention of HIV and sexually transmitted infections and 
advancement of broader sexual and reproductive health in young people necessitates 
evidence-based, tailored, flexible, and client-centred approaches to sexual harm reduction 
and comprehensive sexual education (figure 8).97 Ready access to contraception and other 
family planning services is essential because half of pregnancies in girls aged 15–19 years 
are unintended.98
Changing lifestyles mean that an increasing number of adolescents are susceptible to the 
health risks associated with poor diet, tobacco, alcohol and substance abuse, malnutrition 
(including anaemia and obesity), and NCDs such as diabetes and cancer. In turn, these risks 
are associated with preventable mortality in adulthood. Mental health issues are among the 
top five causes of adolescent disability-adjusted life-years (DALYs) lost, with more than 
75% of mental illnesses originating before age 24 years.99
All adolescents have the right to accessible health services. Helping youth to prioritise health 
and engage in services is challenging when low mortality and good health is expected in 
young people, prior experience in health-care interaction is limited, and concern about 
confidentiality breaches is high.99 Among the key lessons learned in the HIV response is 
that health services must be tailored to young people’s needs and preferences and should 
offer an integrated combination of services. Integrated service packages must include 
comprehensive health checks relevant to adolescents and take into consideration other 
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priorities such as education and economic opportunities, which, if unaddressed, lead to poor 
health and wellbeing.89
Achieving universal health coverage demands the availability of adolescent-focused health 
services in all health facilities and in other more accessible multipurpose spaces. 
Adolescent-friendly services offer operating hours outside of work or school, create a 
friendly and non-judgmental environment, engage peers in support functions, promote health 
in ways that appeal to young people, and use modern technologies and innovations already 
incorporated in the daily lives of adolescents.100,101
Meeting the needs of women—Women’s health needs often differ from those of men. 
Whereas breast cancer is not a leading cause of death in men, the breast is the most common 
site of cancer diagnosis in women (accounting for 25% of all cases in 2012).44 Cervical 
cancer is the fourth leading cancer diagnosis in women and the fourth leading cancer-related 
cause of death in women.44 Although maternal mortality has decreased, an estimated 830 
women die daily from preventable causes associated with pregnancy and childbirth.102
In addition to heightened physiological vulnerabilities to many diseases and health 
conditions, women’s health risks are often closely linked with their unequal status in 
societies. For example, an estimated one in three women worldwide will experience physical 
or sexual violence, and those women who do are roughly twice more likely to experience 
depression or have an alcohol use disorder and 16% more likely to have a baby with low 
birthweight than those women who do not.103
Because of both increased physiological susceptibility to HIV acquisition during penile-
vaginal intercourse and because of gender-related challenges in negotiating safer sex, 
women are especially susceptible to HIV, accounting for 56% of all people living with HIV 
in sub-Saharan Africa.1 Women’s experience of intimate partner violence has been 
correlated with a 50% increase in the risk of HIV acquisition,104 and emotional abuse by 
partners is linked with rapid progression of HIV disease in women.105
The HIV response has long joined forces with the broader women’s health agenda through 
political advocacy for gender equality, programmes to promote healthy gender norms, and 
strategies to prevent gender-based violence. At national, regional, and global levels, women 
living with HIV have organised networks to provide mutual support and to increase 
recognition of HIV as a women’s health issue. Substantial resources have been invested in 
condom programming and other interventions to reduce women’s sexual risks and in 
research to develop prevention methods that women can control on their own.
The successful global scale-up of ART in women has shown the feasibility of achieving 
broad access to care for women. Among people living with HIV, women are more likely 
than men to know their HIV status, receive ART, and achieve viral suppression.5 The 
proportion of pregnant women living with HIV who receive effective antiretroviral 
medicines increased from 47% in 2010, to 76% in 2016.5
There is growing recognition that the women’s health agenda must move beyond its 
traditional focus on sexual and reproductive health and tackle women’s growing burden of 
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NCDs.105 The Pink Ribbon Red Ribbon partnership, working in six countries in sub-
Saharan Africa and Latin America, aims to leverage momentum and infrastructure from the 
HIV response to reduce the cancer burden in women. Through the third quarter of 2017, the 
partnership reported that it had screened more than 465 000 women for cervical cancer and 
more than 34 000 women for breast cancer, administered the vaccine for human 
papillomavirus to nearly 148 000 girls, and provided treatment services to almost 30 000 
women diagnosed with cervical cancer.106
The gender gap in health: services for men—Health outcomes are consistently 
worse in men than in women. In 2015, mean life expectancy was 5·8 years higher in women 
than in men (74·8 years [uncertainty interval 74·4—75.2] for women vs 69–0 [68·6–69·4] for 
men), and this gender gap in life expectancy is increasing over time.107 These patterns are 
vividly reflected in HIV-related outcomes; in 2016, men accounted for less than half of all 
adults (>15 years) living with HIV but for an estimated 58·4% of AIDS-related deaths.1
A key driver in gender differences in health outcomes appears to be men’s comparatively 
lower utilisation of health services. In a national survey in 2013,108 men in the USA were 
markedly less likely than women (72% vs 86%) to report a regular source of care or to report 
having seen a health-care provider in the previous 2 years (75% vs 91%). Across regions, 
men are consistently less likely than women to know their HIV status, to receive ART, and 
to remain engaged in care once they initiate HIV treatment.5
In many countries, especially in LMICs, the best developed health-service delivery 
platforms (eg, antenatal, maternal, paediatric, sexual and reproductive services) are often 
designed primarily for use by women or children, or both. In many settings, few, if any, 
health-service delivery channels have been developed specifically with men in mind. This 
has led to the common belief that clinics are not meant for men,109 deterring men from 
accessing health services. Often, health services are accessible only during working hours, 
further discouraging male workforce participants from obtaining the services they need. 
Popular notions of masculinity might also disfavor receipt of health services as a sign of 
weakness.110
In view of the severe gender gap in health, it is striking how little attention the HIV response 
or the global health field has given to men’s health issues. To close the gender gap, decision 
makers must expressly value men’s lives and prioritise action to increase men’s access to 
and use of health services. In the case of HIV, a growing body of evidence suggests that 
community-centred programmes that specifically work to engage men and address their 
needs and preferences (including flexible clinic hours, mobile services, workplace 
programmes, and private access) can effectively diminish the gender gap in men’s utilisation 
of health services.111 To reach nearly 15 million men with voluntary medical male 
circumcision in 14 African countries in 2008–16, and thereby avert more than 500 000 new 
HIV infections through 2030,60 circumcision programmes worked with men and local 
communities to forge new social norms, offered services at hours that corresponded to men’s 
needs, used a variety of service delivery approaches (eg, mobile outreach), and integrated 
circumcision services with multiple other health services.112
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Innovative service models could diminish or eliminate gender gaps in HIV service utilisation 
(figure 9). SEARCH, a community-centred research project in 32 rural communities in 
Kenya and Uganda, integrated HIV testing in multidisease health fairs and used innovative 
approaches to deliver ART through co-located services. To help avoid a gender gap in testing 
utilisation, SEARCH created men-only discussion groups that invited men to discuss HIV 
and sexual health issues. After 2 years of the intervention, gender gaps across the 90–90-90 
cascade had effectively disappeared, with men achieving the first two 90s and 88% viral 
suppression.113
People who inject drugs—One of the great ironies with respect to the prohibitionist 
approach to substance use, which treats drug use primarily as a law enforcement and 
national security matter and continues to have widespread and negative implications for 
HIV114 and global health more generally, is that it was initiated in the name of public health. 
A further irony is that these failed policies also spawned one of the most successful of all 
HIV prevention strategies. Harm reduction is a practical and rights-based approach that aims 
to mitigate the negative consequences of behaviours, including when cessation of the 
behavior is infeasible or not desired by the individual. This approach has potential 
applicability to a host of health problems beyond blood-borne pathogens such as reducing 
alcohol-related problems, minimising road trauma, and preventing skin cancers. Harm 
reduction needs be seen as a core global health promotion strategy.
For prevention of HIV and viral hepatitis, harm reduction has traditionally referred to a 
range of services that include the provision of clean needles and syringes (NSPs). Combined 
with access to medication-assisted therapy (MAT), NSPs continue to be the most effective 
strategy to reduce new HIV infections in people who inject drugs. Harm-reduction services 
have the added public health benefit of facilitating linkages to other HIV-related services, 
drug treatment, and primary health care. Harm reduction is increasingly being adopted in 
diverse settings, although large gaps in the scale and coverage of harm-reduction 
programmes limit the ability of many countries to halt HIV and HCV epidemics.115 The 
USA, long a leading proponent of the global war on drugs, appears poised to undertake a 
rapid expansion of MAT in response to a surge in opioid addiction, offering potential 
opportunities to alter the global discourse on harm reduction.
To reduce the negative consequences associated with drug use, expansion of harm-reduction 
services also needs to be coupled with broad-based reform of laws and policies. Incremental 
progress has been made in reforming UN drug conventions to incorporate certain health and 
human rights considerations, but a wholesale paradigm shift in the global approach to drug 
use has yet to occur.116 Needed legal reforms (eg, decriminalisation, proportional 
sentencing, or diversion to health and social services for non-violent offenders) will not only 
facilitate greater access to health and social services for susceptible communities but also 
sharply reduce prison populations. Reductions in the prison population might free up 
resources for scaling up ART, drug treatment, and primary health care in prison settings and 
reduce the incidence and risk of infectious diseases. In pursuing locally tailored drug policy 
reform, nation states and states within nation states can help build a compelling evidence 
base that can guide and inform reform efforts, unlock new efficiencies in prison systems, and 
build new constituencies for drug policy reform. To transcend polarising political debates 
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that have limited its support, harm reduction itself needs to expand and mainstream its ethos 
and more integrate its application beyond drug use across a wider spectrum of stakeholders 
and public health issues.
Gay and bisexual men—In 2016, 12% of all new HIV infections worldwide and 22% of 
all incident infections outside sub-Saharan Africa were in gay men and other MSM.117 
Among HIV risk behaviours, HIV acquisition from condomless and receptive anal 
intercourse is twice more likely than from needle sharing during injecting drug use and more 
than 17 times more likely than from receptive penile-vaginal intercourse.118
However, gay men’s disproportionate HIV burden cannot be disentangled from their 
profound (and in many settings, worsening) social disadvantages. In 2017, more than 70 
countries criminalised consensual same-sex relations,119 and the legal and policy barriers 
confronted by gay men have only increased in recent years, including through enactment of 
Russia’s so-called gay propaganda law and a draconian anti-gay law in Nigeria that went 
into effect in 2014. The past 2 years witnessed a sharp increase in the number of arrests of 
gay men in Indonesia120 and the forced closure of drop-in clinics providing HIV and other 
health and social services to gay men in Tanzania.121
Such a climate of fear and hostility inevitably increases gay men’s susceptibility to HIV and 
reduces their access to essential prevention and treatment services. In India and in Moscow, 
only a small minority of gay men living with HIV have achieved viral suppression, with lack 
of knowledge of HIV status serving as the most serious service bottleneck.122,123 Coverage 
of PrEP, a potentially transformative prevention tool for gay man and other marginalised 
populations, is only minimal outside of high-income countries.5
A crucial barrier to a more effective HIV response for gay men (and an unfortunate 
reflection of the neglect of gay men’s needs) is the shortage of robust evidence for action in 
this population. Although findings from focused studies continue to demonstrate 
extraordinarily high HIV prevalence and incidence in gay men in broadly diverse settings, 
evidence on gay men from standard surveillance systems is extremely limited, primarily 
because these systems focus on adults of reproductive age, especially in high-burden 
settings. Many countries still have no estimates of the size of the gay population, and half of 
those countries with estimations employ methodologies that call the reliability of these 
estimates into question.124
Migrants and the displaced—The number of people living in a country other than the 
one in which they were born (244 million in 2015) is larger than the population of all but 
four countries.125 In addition to cross-border migration, many people move for work or 
other reasons to different states or provinces within their own country; In China alone, this 
affects more than 280 million rural migrants.126 Worldwide, the migrant population includes 
65·6 million forcibly displaced people, 22·5 million refugees, and 10 million stateless 
people.127
Addressing the health needs of the world’s massive and growing population of migrants is a 
health and human rights imperative.128 However, public health insurance schemes often 
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exclude or limit services for migrants, especially for those who are undocumented. In part 
through regional cooperative compacts, more countries are taking steps to introduce health 
insurance approaches that explicitly cover migrants, yet implementation of these approaches 
remains incomplete129 and many migrant workers in such settings are unaware of the health 
benefits to which they are ostensibly entitled.130
The stigmatisation and scapegoating of immigrants, including the risk of death or injury 
from increasingly coercive border control practices and acts of anti-immigrant violence, 
contribute immeasurably to their susceptibility. Migration could lead to discontinuity and 
fragmentation of health care, a particularly serious problem for people with chronic diseases. 
Health risks are compounded when migration is the forced result of military conflict or 
humanitarian emergency, which can create especially chaotic conditions and prove 
particularly disruptive to service systems. In 2018, results of a phylogenetic analysis in 
Ukraine suggested that migration resulting from civil conflict in eastern Ukraine led to a 
rapid redistribution of HIV infection westward and an apparent increase in HIV drug 
resistance.131
In an increasingly mobile world, steps to address the health needs of people on the move are 
crucial to the future of global health. In the push to achieve universal health coverage, 
countries need to take on board lessons learned from Thailand’s pioneering provision of 
comprehensive health coverage for migrants living within its borders.132 In regions with 
extensive cross-border migration, innovative regional efforts will be needed to ensure 
continuity of care. Migrants should have access to health navigators and other health 
services in their own language. In close collaboration with other civil society partners, health 
advocates should energetically oppose demagogic efforts to stigmatise migrant communities.
Related health issues
To date, the greatest focus on linking HIV with the broader global health field has occurred 
with respect to specific health problems that overlap with HIV. These include diseases that 
share modes of transmission as well as comorbidities that often accompany HIV infection.
HIV, NCDs, and the future of global health—The future of the HIV response is 
intrinsically linked with the future of global efforts to address NCDs. Due to the 
effectiveness of ART, the HIV population is steadily ageing over time, with the number of 
people older than 50 years who are living with HIV increasing by 36% between 2012 and 
2016.1 In 2016, sub-Saharan Africa was home to 3·7 million people (65 %) of the world’s 
people living with HIV who are older than 50 years.1 As people live longer with HIV and 
depend on ART for decades, the care of people living with HIV will increasingly focus on 
prevention and management of NCDs. People living with HIV have an increased risk of 
many age-associated diseases,133 including cardiovascular diseases,134 neurocognitive 
disorders,135 end-stage renal disease, and non-AIDS-defining cancers.136 NCD risks appear 
to be less pronounced for people who initiate HIV treatment at higher CD4 counts and, 
presumably, for those using modern ART regimens with fewer known negative side-effects.
137
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As diverse stakeholders coalesce to create a global movement to address NCDs, experiences 
in the HIV response (including its advocacy successes, community engagement, models of 
care, and innovation to ensure access to essential diagnostics and medicines) potentially hold 
important lessons for the NCD community.138 Already, the global attention to NCDs has 
surged, as reflected in the creation of the NCD Alliance and the Lancet NCD Action Group, 
the upcoming Third High Level Meeting on NCDs at the UN’s General Assembly in 2018, 
the WHO-commissioned Independent High Commission on NCDs, and grassroots 
movements to increase cancer awareness and funding for cancer research. However, much 
greater political commitment, and the willingness to stand up to entrenched financial 
interests such as the tobacco and food industries,139 will be needed if NCDs are to receive 
the attention they warrant.140
The NCD agenda has a clear potential to catalyse action to address the structural 
determinants of health. Structural approaches (ensuring smoke-free environments, banning 
or restricting advertising for tobacco or alcohol products, using taxes to discourage use of 
tobacco or alcohol, reducing salt and sugar content in packaged foods and beverages, and 
replacing trans-fats with healthier alternatives) are pivotal to efforts to reduce NCDs.141 
Given the powerful degree to which socio-economic status influences susceptibility to 
NCDs,142 strategies to alleviate poverty also support prevention of NCDs. As structural 
action to address NCDs requires action in multiple domains (eg, social protection, trade, 
agriculture, taxation and finance, agriculture, manufacturing, labour), it is important that 
health routinely be taken into account in policy development processes. Toward the goals of 
more integrated and universally accessible health systems and sustainable health for all, 
policy development should prioritise structural approaches that generate health benefits for 
diverse populations and health conditions. As prevention of NCDs involve substantial shifts 
in social norms and practices (eg, smoking and alcohol consumption, diet, indoor cooking 
practices), engagement of communities is essential.
For some NCDs, prevention technologies must be brought to scale, actively promoted, and 
made broadly accessible. These include nicotine replacement and other smoking cessation 
tools, as well as vaccines for the hepatitis B virus and human papilloma virus. Cognitive 
behavioural interventions, akin to the behaviour change theories and approaches that have 
been associated with reduced HIV risk behaviours and new HIV infections,7 have a role in 
reducing the modifiable risk behaviours that might increase NCD risks.
Experience in the HIV epidemic has taught that efforts to prevent a disease are often less 
effective if treatment for the disease is unavailable. Until recently, the global health 
discourse on NCDs focused almost exclusively on prevention, implicitly assuming that 
treatments would remain out of reach for the foreseeable future. The growing global 
movement on NCDs, as in the HIV response that preceded it, is rightly insisting on urgent 
action to make NTD treatments affordable and widely available.143
Although the HIV response is justifiably proud of having created service systems capable of 
delivering ART to millions of people, the health-systems challenges associated with NCDs 
are even greater than they were for HIV. Effectively addressing NCDs will require 
reconfiguration of health programmes and individual clinics and will demand new 
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investments in health workforce training and development144 to increase expertise in 
management of cardiovascular disease, oncology, geriatric medicine, radiotherapy, and other 
NCD-related disciplines. Comprehensive and integrated care needs to be established as the 
working norm for health systems, with primary care as the cornerstone. Models of 
community-based and community-delivered care, which prioritise self-care and 
differentiated services for people living with HIV, have potentially broad applicability to the 
management of NCDs.145 Capacitating health systems to address multiple health problems 
in an integrated manner, including through co-located services, will improve efficiencies and 
aid in destigmatising both HIV and NCDs.
In joining hands with the NCD field, the HIV community will also need to evolve. Moving 
forward, the HIV response must transcend its singular, if imperative, focus on viral 
suppression and recognise that prevention and control of NCDs are equally pivotal measures 
of success. Vertical health programmes have driven much of the expansion of health capacity 
in LMICs in recent years; they have also created professional silos that are often jealously 
guarded. Strong action will be needed to overcome these tendencies and persuade diverse 
healthcare cadres and constituencies to understand the transformative potential of more 
integrated and comprehensive approaches that preserve or improve quality. For both national 
governments and international health donors, new funding formulae might be necessary to 
incentivise integrated and multidisease service models.
Multidisease health screening models have already proven effective in addressing not only 
HIV but also hypertension, diabetes, and childhood illnesses.146 To expand the evidence 
base on the benefits and costs of integrating HIV and NCD programmes, the Commission 
conducted modelling exercises to examine the health and financial effect of multidisease 
screening programmes for HIV and NCDs in South Africa and Kenya.
Integration of sexual and reproductive health services—The rationale for 
integrating HIV and sexual and reproductive health and rights (SRHR) services is 
compelling,147 as individuals seeking or needing SRHR and HIV services are likely to face 
interrelated risks (eg, of sexually transmitted infections and HIV infection, unintended 
pregnancy, high-risk pregnancy, perinatal transmission of HIV, gender-based violence) and 
have interrelated needs (for sexually transmitted infections and HIV detection and treatment, 
contraception, antenatal or postnatal care, prevention of mother-to-child transmission, 
pregnancy termination, and sexuality education and counselling). For such patients, the 
ability to receive integrated care (in a single setting, and in a single day) offers substantial 
benefits in terms of convenience and cost. In practice, however, for a range of political, 
strategic, and funding reasons, efforts to integrate HIV with other SRHR services have been 
minimal for much of the pandemic’s history.
Funding and structures created to respond to the global AIDS crisis, while critical to saving 
lives, contributed to the separation of HIV and SRHR: the establishment of UNAIDS in 
1996, which anchored HIV firmly outside of the SRHR framework; the MDGs in 2000, 
which ignored SRHR altogether and defined a separate goal for HIV/ AIDS; and the Global 
Fund, which has been a lifeline to millions of people around the world, but, at the time of its 
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creation in 2002 and until relatively recently,148 focused little attention or funding on SRHR, 
except with respect to services to prevent vertical transmission of HIV.149
The separation of HIV from SRHR in these structures and funding mechanisms contributed 
to an over-medicalisation of the HIV response and shifted attention away from addressing 
the epidemic in the context of sex and sexuality. Consequently, other elements of SRHR (eg, 
abortion, contraception, and comprehensive sexuality education for youth) became easy 
targets for political agendas already seeking to eliminate access to such services. Moreover, 
this separation has undermined efforts to firmly establish HIV and SRH service delivery in a 
human rights framework, prioritising bodily autonomy, sexual rights, and access to 
information and services,150 which has been a contributing factor to violations of sexua and 
reproductive rights of women living with HIV, such as the use of forced or coerced 
sterilisation or abortion.151
Although notable, if uneven, progress has been made in integrating services for the 
prevention of mother-to-child HIV transmission in broader SRHR approaches,152 progress 
in addressing the SRHR needs of women, girls, and sexual minorities remains wholly 
inadequate. Even in high-burden settings in sub-Saharan Africa, where a substantial number 
of women need services to prevent both unintended pregnancy and HIV, integrated services 
are rare.153 Marginalised populations at increased risk of HIV infection (including sexual 
minorities) have additional SRHR needs that are often unaddressed by SRHR services that 
primarily cater to married or coupled women of reproductive age.153
Integrated definition of sexual and reproductive health and rights—The 
Guttmacher-Lancet Commission on Sexual and Reproductive Health and Rights154 defines 
sexual and reproductive health as “a state of physical, emotional, mental, and social well-
being in relation to all aspects of sexuality and reproduction, not merely the absence of 
disease, dysfunction, or infirmity. As such, a positive approach to sexuality and reproduction 
should recognize the role played by pleasurable sexual relationships, trust, and 
communication between partners in promoting self-esteem and overall well-being”. The 
Commission defined an essential package of sexual and reproductive health interventions 
and emphasised that the achievement of sexual and reproductive health depends on 
realisation of sexual and reproductive rights, which are based on the human rights of all 
individuals to: have their bodily integrity, privacy, and personal autonomy respected; freely 
define their own sexuality, including sexual orientation and gender identity and expression; 
decide whether and when to be sexually active and choose their sexual partner (or partners); 
decide whether, when, and by what means to have a child or children, and how many 
children to have; and have access over their lifetimes to the information, resources, services, 
and support necessary to achieve all the above, free from discrimination, coercion and 
violence.
Effective integration of HIV and SRHR services requires action in diverse health service 
domains, including contraception, maternal and newborn care, and abortion services. In 
2017, 43% of the 206 million pregnancies in LMICs were unintended, and 84% of these 
unintended pregnancies were in women who had an unmet need for modern contraception.98 
In 2017, 37% of women who gave birth in developing countries did not receive the 
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recommended minimum of four antenatal care visits, 28% gave birth outside a health 
facility, and 308 000 women in developing countries died from pregnancy-related causes.98
HIV-SRHR service integration can occur either by introducing HIV prevention and testing 
into the current suite of contraceptive, maternal and child care, and abortion services or by 
improving access to these types of SRHR services for people living with HIV. When HIV 
and SRHR services are functionally integrated, important improvements can be achieved in 
HIV testing rates, condom use, and selected indicators of quality of care.153 We modelled 
these interactions for the potential benefit of integrated services in Nigeria (figure 10).
The important intersections between use of specific hormonal contraceptive methods and 
various HIV-related risks further buttress the rationale for integration of contraceptive and 
HIV services. Observational data suggest a potential association between use of the 
progestin-only injectable contraceptive depot medroxy-progesterone acetate (DMPA) and 
risk of HIV acquisition in women exposed to the virus.155 In updated guidelines, WHO in 
February, 2017, recommended that women considering use of progestin-only injectables be 
advised about these concerns, the uncertainty over whether the association is causal, and 
how to minimise their risk of acquiring HIV.156
Services for the prevention, diagnosis, and treatment of sexually transmitted infections offer 
an important platform for integrating HIV in broader SRHR services. Fully capturing the 
potential synergies and complementarities between sexually transmitted infections and HIV 
prevention will necessitate a more holistic and context-specific approach to sexual health. As 
an example of HIV-STI integration, the Dean Street Express clinic in London, UK, provides 
a comfortable drop-in facility where individuals input sexual risk information in kiosks, 
privately self-collect their oral, rectal, and genital specimens for detection of sexually 
transmitted infection, have specimens delivered via pneumatic tube to an onsite laboratory, 
and receive their results via text messaging within several hours. Another approach to 
enhance sexual health is the New York City PlaySure sexual health programme, which 
educates at-risk persons that HIV medications used for treatment, PrEP, or post-exposure 
prophylaxis (PEP) can protect the health of individuals irrespective of serostatus. Paired with 
an integrated package of sexual health services that include routine sexual health screenings 
and rapid initiation of antiretroviral medications for either prevention or treatment, New 
York’s Status Neutral model uses sexual health services as a gateway to transition from 
safety net services to more longitudinal and comprehensive care.
Scaling up an integrated and synergistic approach to sexual health confronts important 
obstacles that will need to be overcome. Notably, many primary care providers do not 
routinely ask important questions about sexual health. Because medical and professional 
schools often omit sexual history taking in medical training, health workers often miss 
important opportunities for prevention and fail to provide their patients with good-quality 
services.
Transcending the historic separation between HIV and sexual health will rely on bold 
leadership, innovative approaches, new funding models, and new partnerships that help 
dissolve the siloes in which these related efforts have operated. Integrating HIV and SRHR 
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will help ground these linked enterprises in a human rights framework that prioritises bodily 
autonomy, sexual rights, and access to information and services.
Global health emergencies: Ebola, Zika, pandemic flu, and antimicrobial 
resistance—Global health emergencies related to infectious diseases in recent years have 
highlighted the pressing need for all countries to be prepared for the advent of health 
emergencies and have the capacity to respond rapidly and effectively. In recent years, the 
Ebola, Zika, and pandemic influenza viruses moved through specific regions quickly, with 
devastating effects on people’s lives, communities, and economies. With increasing 
population pressure, urbanisation, travel and displacement, climate change, habitat 
destruction, and global antimicrobial use, the world will inevitably see more frequent health 
emergencies related to infectious diseases.157 Some of these emergencies are highly likely, 
such as pandemic influenza, which will always reappear.158 Others emergencies such as 
Middle East respiratory syndrome or severe acute respiratory syndrome might be entirely 
new infections that will require rapid collection of data to understand the natural history. 
New presentations could be of known infections but in non-immune communities, as 
recently seen with the Zika virus outbreak, or the emergence of drug-resistant strains of 
known pathogens, including Mycobacterium tuberculosis and HIV.159
Many disease-control interventions are relevant irrespective of the particular health 
challenge, including community-based care delivery, the requirement for and training of a 
diverse health workforce able to handle infectious diseases, control of nosocomial spread, 
research methodology, and infrastructure for effective community engagement (figure 11). 
All infectious disease emergencies require strong laboratory and surveillance systems to 
detect and understand the rapidly changing epidemiology and drive an evidence-informed 
and country-specific response. The HIV response has been an example of community 
engagement and empowerment that has led to accelerated research and more effective 
programme implementation in many parts of the world. The strengths of the HIV response 
can therefore inform responses to global health emergencies.
Although modes of transmission might vary in each health emergency, comparable groups 
are often at risk of multiple diseases, and similar interventions are available to block 
transmission. For example, both Zika and Ebola virus infections were sexually transmissible 
and transmissible from mother to child. As in the case of HIV, fears and suspicion of people 
infected with Ebola virus, and to a lesser extent Zika virus, have prompted calls for 
quarantine, with associated paranoia and misinformation.160 Often, infections and their 
associated stigma disproportionately affect the reproductive rights of women. Dispelling 
stigma and ensuring a non-discriminatory and evidence-informed response is important to 
balance the rights of individuals with appropriate disease control measures.
Although there is much common ground, health emergencies differ in important respects 
from HIV. First, whereas the HIV epidemic is a long-wave event that has unfolded over 
many years, health emergencies in infectious diseases are often acute, leading to major 
short-term disruption. Second, a very rapid political response is needed, often with 
mobilisation of vast amounts of money, which might shift resources away from HIV 
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programmes. Third, there is a limited research base, and few or no known interventions at 
the time an emergency response is needed.
In the absence of an activist community, inappropriate decisions in health emergencies can 
be made for and not with affected communities. In the HIV response, these communities 
have been built, strengthened, and sustained over decades, not days or weeks. The affected 
community might not always be easily defined, as, for example, seen in pandemic influenza 
epidemic or in the case of co-infection and overlaps in disease susceptibility. Infectious 
disease emergencies can profoundly disrupt health services and supply chains, leading to 
cascading health-system failures that affect people with a wide range of diseases.161
Integration of HIV and global health responses could be assisted by a high-level political 
platform bringing people and organisations together to transcend administrative and 
academic silos and to build broadly responsive and effective health systems. Identifying key 
stakeholders in emergency response preparedness and resource mapping of relevant 
capabilities in laboratory diagnostics, surveillance and epidemiology, clinical care, clinical 
trials capabilities, ethics, and target communities will facilitate integration. Investment in 
communication across sectors could enable the development of a business model for rapid 
mobilisation of resources and effective responses to global health emergencies.
Tuberculosis—The basic approach to controlling the linked epidemics of HIV and 
tuberculosis is deceptively straight-forward. People with HIV-tuberculosis co-infection who 
develop active tuberculosis disease need to be found and treated promptly with tuberculosis 
drugs and ART. Co-infected individuals at risk of developing tuberculosis must be treated 
with ART and with isoniazid preventive therapy (IPT).
In reality, however, controlling tuberculosis in the context of HIV has proven to be a major 
global health challenge. Globally, less than half of tuberculosis cases are diagnosed before 
death, and only about half of all patients with tuberculosis know their HIV status.162 Less 
than half of all people living with HIV who have tuberculosis are estimated to be receiving 
ART, but HIV treatment coverage is 77% among notified tuberculosis cases.162 In 2016, 
60% of countries with high HIV-tuberculosis burden did not report the provision of IPT.162 
Despite these challenges, the improvements in HIV care and treatment, recognition that both 
diseases coexist, and a move to more active case finding led to a reduction in annual 
mortality from tuberculosis in people living with HIV by 33% between 2005 and 2015.1
The global failures to address tuberculosis in the context of the HIV epidemic demonstrate 
the challenges of service integration, even when the biology of pathogens and the clinical 
realities of disease interactions clearly argue for integration. Tuberculosis and HIV 
programme siloes are object lessons in the difficulties of providing better and more 
streamlined care for patients in dual epidemics. Inadequate HIV-tuberculosis integration 
results in suboptimal service coverage, limited access, missed opportunities for prevention, 
diagnostic and therapeutic intervention, and inefficient use of resources.
Although undoubtedly beneficial, integration of HIV and tuberculosis services is not always 
easy to achieve. Infection control, particularly in health-care settings, is necessary but often 
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difficult under existing conditions, with multidrug-resistance tuberculosis and extreme 
multidrug-resistance tuberculosis posing lethal risks for people living with HIV. Health 
workforce shortages undermine effective management and control of HIV-tuberculosis co-
infection, and health workers addressing HIV-tuberculosis co-infection are also at substantial 
risk of occupational exposure to tuberculosis. As HIV and tuberculosis programmes were 
developed separately, with different funding streams and constituencies, ensuring ongoing 
communication and collaboration between these programmes might be hindered by 
resistance from turf-conscious programme implementers and planners. Tuberculosis and 
HIV-tuberculosis co-infection are particularly challenging issues for incarcerated persons 
worldwide.163 According to a review of HIV, viral hepatitis, and tuberculosis burden in 
prisoners and detainees, the most effective way to reduce these infections in prisoners and in 
the broader communities from which they come is to reduce mass incarceration for people 
who inject drugs.163
Numerous efforts worldwide, often extremely successful, have been made to improve HIV-
tuberculosis collaboration and linkages. In Khayelitsha, South Africa, HIV and tuberculosis 
programmes were physically merged in 2003 to enable so-called one-stop shopping for 
people with HIV-tuberculosis co-infection.164 In Tanzania, PASADA, a faith-based 
organisation providing comprehensive HIV care, collaborated with national tuberculosis 
authorities to integrate tuberculosis services and improve laboratory capacity, harmonise 
staff training and reporting, dedicate a room within the clinic for patients with tuberculosis, 
and link services with a strong social support system. In India, collaboration at the national 
level has driven systematic implementation of collaborative HIV-tuberculosis activities 
across the country.
Notwithstanding these promising examples, HIV and tuberculosis programmes continue to 
operate independently in most parts of the world. Joint efforts are warranted for coordination 
of national responses to HIV and tuberculosis, including strengthened surveillance, 
programme planning, and monitoring and evaluation. Intensified tuberculosis case finding, 
scaled-up IPT, and a strengthened emphasis on infection control are needed to reduce the 
tuberculosis burden in people living with HIV. Further efforts are needed to ensure routine 
HIV testing, access to HIV prevention methods, ART, and HIV care and support for patients 
with tuberculosis. Collaborative programmes for HIV and tuberculosis should build on well 
developed community systems and civil society engagement and incorporate interventions 
for poverty alleviation and social protection as well as specific measures to reduce the HIV 
and tuberculosis burden in prisoners and migrants. Collaborative HIV-tuberculosis 
programmes must be prepared to manage the most common co-occurring health conditions 
in individuals with HIV-tuberculosis co-infection such as diabetes, alcohol and drug use 
disorders, health conditions related to tobacco smoking, and lung diseases. These 
strengthened collaborative programmatic efforts should be supported by robust investments 
in research and innovation that will support the discovery, development, and rapid uptake of 
new tools and interventions as well as the research to optimise implementation and catalyse 
further innovation.
Viral hepatitis—The links and synergies between HIV and viral hepatitis are evident, in 
part because of overlapping routes of transmission, overlapping populations at highest risk 
Bekker et al. Page 33
Lancet. Author manuscript; available in PMC 2019 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of acquisition and transmission, and common approaches to prevention and treatment. HCV 
infection, however, by marked contrast with HIV, is now curable. With a relatively short 
course and well tolerated oral therapy, a cure is reliably achieved in more than 95% of 
infected persons.165 Isolation of HCV and development of a curative regimen are recent 
developments, and there is reason for hope that rapid gains can be made in diminishing the 
burden associated with the infection. Hepatitis B virus was isolated much earlier than 
Hepatitis C virus, and global coverage of the vaccine, which is cheap and effective, for 
newborn babies reached 84% in 2016.166
The HIV epidemic, including the desperation for effective therapies it elicited in its early 
years and the changes it wrought to drug development, regulatory policies, and the global 
infrastructure for clinical trial enrolment, laid the foundation for the development of the 
highly effective, safe, all-oral, curative therapies that have emerged for HCV infection. As in 
the case of HIV, originator companies have entered voluntary license agreements with 
generic manufacturers to produce and distribute direct-acting antivirals, which has 
substantially lowered treatment costs in the LMICs covered by these agreements. Due to 
differences in epidemiological burden between HIV and HCV, with substantial concentration 
of HCV infection in many upper-middle-income countries and high-income countries that 
are excluded from voluntary licenses for direct-acting antivirals, costs of these drugs remain 
prohibitive in many parts of the world.167
Community mobilisation has had an essential role for responses to both HIV and HCV. Civil 
society mobilisation to expand treatment access for HCV infection is rapidly increasing to 
demand development of national treatment guidelines, innovative use of intellectual property 
law to lower the cost of direct-acting antivirals, and routine availability of diagnostic and 
therapeutic tools.
Treatment as prevention, a concept made feasible by the advent of effective therapies to 
achieve HIV control, has the potential to be realised for HCV infection through expanded 
use of direct-acting antivirals, the first highly effective curative treatment for a chronic viral 
disease. Elimination of HCV would inspire the global health field and generate important 
lessons pertinent to efforts to control other infectious diseases through the delivery of safe, 
effective, and short-term treatment to marginalised populations.
To realise the elimination goal for viral hepatitis, a major shift will be required in the 
management of these diseases. Here, too, lessons from the HIV response are instructive, 
notably the evolution in HIV treatment from a focus on the sickest to recognition of the 
benefits of treatment for all people living with HIV. Treatment for HCV infection is often 
reserved for the sickest patients, and many people who could benefit from treatment have 
been denied therapy because of risk behaviours (eg, ongoing injection drug use). As the right 
to treatment has proved such a powerful and animating force in the HIV response, a similar 
rights-based approach is needed to ensure the access of all people with chronic HCV 
infection to treatment services.
In yet another echo of experience with HIV, the HCV treatment revolution has the potential 
to draw marginalised people into health services that have historically been hostile or 
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unwelcoming. Health systems must adapt to provide the needed array of health and social 
services for vulnerable populations. The HCV response, like the HIV response, brings into 
sharp relief the importance of ensuring investment in research and development of new 
medicines, maintaining sustainable health budgets, and leveraging social and health policy to 
prevent the spread of infectious diseases.
Differentiated care for HIV—Models of service delivery developed for the rapid scale-up 
and maintenance of ART are potentially useful for informing care strategies for other 
diseases, including the growing burden of NCDs. Taking what began as a standardised and 
somewhat rigid approach to the delivery of HIV treatment, people living with HIV and the 
communities in which they live pioneered new approaches to service delivery.
Although these adaptations are diverse, they share the central idea of responding to client 
and health systems needs. In rural Mozambique, groups of clients took turns travelling to the 
health centre to collect refills of antiretroviral medicines to avert the need for individual 
patients to travel long distances for monthly refills.168 Networks of people living with HIV 
in Uganda opened community drug distribution points closer to communities to enhance 
access.169 In urban South Africa, adherence clubs offered peer-based adherence support and 
reduced the frequency with which virally suppressed clients needed to attend clinic, helping 
decongest overcrowded clinics.145 Importantly, these service delivery innovations not only 
increase client convenience and minimise health-system burdens, but they also generate 
excellent health outcomes, as measured by retention in care and rates of viral suppression.
170
Together, these various service delivery adaptations have become known as differentiated 
service delivery. Consistent with a people-centred approach to health care, differentiated 
service delivery recognises and responds to the diversity of client needs.171 In 2016, WHO 
formalized the paradigm shift in HIV service delivery, replacing the standardised one-size-
fits-all model, which had long been recommended for HIV services, with distinct packages 
of care for different groups of people living with HIV.172 Differentiated service delivery 
illustrates not only how service delivery innovations can improve efficiency and 
effectiveness but also how communities can shape and inform health systems.
Substance use disorders—Marginalised communities, including but not limited to sex 
workers and sexual minorities, often experience addiction in the context of multiple health 
and social disadvantages (eg, mental health disorders, abuse, police harassment, 
homophobia, and transphobia).173,174 In particular, the criminalisation of substance use and 
of substance users has long aided and abetted transmission of HIV and other diseases.175 
The regions where the HIV pandemic continues to expand (eastern Europe and central Asia, 
the Middle East, and north Africa) share substantial HIV epidemics in people who inject 
drugs and have harsh prohibitionist drug regimes.175 In Russia, home to the largest epidemic 
in eastern Europe and central Asia, all opioid substitution therapy is illegal and the country 
instead relies heavily on coercive detention for rehabilitation (figure 12).76 In the USA, an 
expanding opioid epidemic has led to outbreaks of HIV and HCV, especially in rural 
communities where a high proportion of new cases are young, white women.176
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Untreated substance use disorders are associated with reduced retention in HIV care and 
worsened HIV-related health outcomes.177 Drug dependency requires intensive, personalised 
treatment such as MAT with methadone, buprenorphine, and other opioid agonists. These 
services for drug addiction are fully compatible with HIV prevention and treatment services, 
including HIV testing and provision of ART, PrEP, syringes, condoms, and overdose 
prevention (eg, naloxone). A team in northeast USA developed culturally tailored 
programmes that use innovative means to provide MAT, work with correctional systems, and 
understand the interplay between substance use, violence and victimisation, sex work, and 
behavioural health morbidities.178 This approach was subsequently adapted to other settings, 
including Ukraine and Malaysia.
Globally, integration of HIV and addiction services is scarce, in part because of stigma. 
People with substance use disorders are often excluded from MAT or other services if they 
have a comorbid psychiatric disorder (and vice versa), an approach that not only worsens 
health outcomes but also compounds the marginalization experienced by people with these 
disorders. In many settings, treatment for substance use and HIV operate in silos, resulting 
in fragmented care and suboptimal clinical outcomes. Meaningful integration of services for 
people with substance use and HIV requires a health workforce that is culturally competent 
and professionally skilled to create clinical environments that promote service access, 
engagement, retention, and medical adherence. Modelling exercises on behalf of the 
Commission examined the epidemiological and cost effect of such a one-stop shopping 
approach for people who inject drugs in Russia.
Mental health disorders—There are multiple reasons for the frequent co-occurrence of 
mental health disorders and HIV, with many stemming from the internalised stigma and 
stress that are often associated with behaviours that can result in HIV transmission (eg, sex 
between men, gender variance, or injecting drug use).179 Internalised stigma associated with 
HIV is common not only in marginalized populations but also in settings with high-burden 
epidemics in heterosexual people, linked in many cases to shunning or shaming by families, 
friends, and social arbiters, including faith leaders. In one recent US cohort, more than one 
in five patients had clinically significant depression, 22% of the cohort had an anxiety 
disorder, and a comparable proportion of the cohort had a clinically significant substance use 
disorder.180
The linkages and overlaps between HIV and mental health are multifaceted. Depression, 
especially when it occurs alongside substance use and other health and social conditions, can 
contribute to risky sexual behaviours.181 Untreated depression is also correlated with 
reduced capacity for self-care and retention in HIV care.182 These associations are hardly 
unique to HIV as untreated depression and other psychiatric disorders are strongly linked 
with non-adherence in patients with cardiovascular and other NCDs.183 One of the most 
striking features of the intersection between HIV and mental health is the common co-
occurrence of multiple coexisting psychosocial and clinical challenges in people with or at 
risk of HIV.184 The presence of these syndemic conditions potentiates sexual transmission 
risk182 and non-adherence to antiretroviral medication regimens.172
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Because of the centrality of mental health to the management of a broad array of health 
conditions, mental health services should be fully integrated into the health system and 
ideally co-located with other related health services such as treatment and care for HIV, 
NCDs, and substance use disorders.185 However, as confirmed by findings from a situation 
analysis in five LMICs, most health systems are not prepared to provide an integrated and 
scaled-up access to mental health services.186 Although mental health disorders are one of 
the leading causes of disability worldwide52 and one in four people will need mental health 
services at some point in their lives, many countries invest as little as 2% of total health 
spending on mental health services.187 Immediate efforts are needed to implement the 
actions outlined in WHO’s mental health action plan 2013–20.188 Implementation of these 
action steps will require major new investments in mental health training for health 
personnel and a decentralisation of mental health services to increase access to community-
based services.189
Health systems and structural change
Perhaps more than any health problem of our time, HIV has shown both the importance of 
strong health systems and how social, legal, economic, and structural factors affect 
susceptibility to disease and the capacity of societies to mount effective public health 
responses. To date, however, the success of the HIV response in addressing these social and 
structural factors has been imperfect at best, in part due to the failure to translate key insights 
into meaningful policies and programmes. The Agenda for Sustainable Development, which 
is premised on the indivisibility of the broader development agenda, affords new 
opportunities to integrate attention to social and structural issues as a fundamental pillar of 
global health. Indeed, although health-specific targets are clustered under SDG 3, the future 
of global health is integrally linked with the vision of SDG 16 to “promote peaceful and 
inclusive societies for sustainable development, provide access to justice for all and build 
effective, accountable and inclusive institutions at all levels”. Such important change will not 
be easily achieved, but the long-terms benefits could be substantial.
Just as disease-specific and population-specific funding for health can create silos that 
impede greater integration, having separate budgets for health and other social sector 
programmes makes it difficult to address the social and structural issues that increase 
susceptibility to disease and diminish use of health services. Health outcomes are affected by 
outcomes from other sectors such as education,190 housing,191 human rights, gender and 
women’s rights, and law enforcement. Other sectors also have a crucial role in delivering 
services that address the needs of people affected by HIV or other health problems; for 
example, social protection that provides cash transfers or undertakes programmes to address 
the needs of susceptible households.
Overcoming these silos will need a clear and strong political mandate for diverse sectors and 
ministries that maximise and fully leverage policy and programmatic synergies as well as a 
strong commitment of each of these sectors to work together. Incorporating multi-sectoral 
approaches in budgetary and strategic planning is a potentially valuable avenue for 
addressing social and structural issues. Under this approach, key sectors or ministries 
participate in formal health planning processes, receive clear budgetary outlays associated 
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with concrete deliverables, and participate in monitoring, evaluation, and accountability 
systems to ensure that these social interventions achieve desired health outcomes.
Building strong health systems—Across diverse populations and disease priorities, 
health system weaknesses impede efforts to improve health and wellbeing and to advance 
towards the goal of universal health coverage.
Well functioning health systems will be essential to sustaining ART in the decades to come 
and to promoting holistic, client-centred, one-stop-shopping models that integrate diverse 
services. New service delivery models that prioritise patient self-care and decongest clinics 
will be needed, and innovative approaches will be necessary to maximise outcomes from 
available health personnel.
Urgent and sustained efforts are needed to build and preserve human resources for health. In 
addition to essential new investments in traditional medical education, the shifting or sharing 
of clinical tasks from higher-cadre to lower-cost health workers will be needed to improve 
health-service efficiency and expand the reach of health services, especially for remote and 
marginalized communities. Increased use of trained community health workers offers an 
important task-shifting strategy for rationalising health spending and bringing services 
closer to the communities that need them. Compensation and training costs for community 
health workers are much less than for higher-cadre health workers, and the availability of 
community health workers enables doctors and nurses to focus more time on the skills for 
which they are specially trained.192 Numerous models for community health workers are 
already in operation in diverse regions, including in high-income countries. Ideally, 
community health workers are drawn from the communities they serve, receive extensive 
training that enables them to diagnose and address multiple health conditions, and are 
compensated, supervised, and fully integrated into health systems. Integrating community 
health workers into health systems has been shown to increase immunisation rates, enhance 
access to diverse health services, and reduce childhood mortality.193–195
The financing of health care can have a major effect on the efficiency of health services. To 
improve efficiency and quality of care, policy makers are advised to optimise the mix of 
payment strategies (eg, capitation, case-based reimbursement, fee-for-service, per diem) that 
incentivizes service access, quality of care, satisfaction of provider and client, and other 
system priorities.196 Evidence suggests that carefully designed financial incentives to 
patients could increase use of preventive care, which improves health outcomes and 
potentially averts more costly therapeutic interventions in the future.
The HIV response has undoubtedly generated benefits for health systems. An independent 
evaluation of PEPFAR found that the bilateral programme had increased national capacity 
for commodity forecasting, procurement, storage, distribution, and tracking.197 Beginning in 
2013, the Global Fund began soliciting proposals not only for specific disease programmes 
but also for health-systems strengthening. Global Fund grants have underwritten a variety of 
activities to buttress procurement and supply management, including expanded warehousing 
capacity in Tanzania, digitising and streamlining supply logistics in Laos, and revising and 
updating of the essential medicines list in Cambodia (Shakarishvili G, Global Fund to Fight 
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AIDS, Tuberculosis and Malaria, personal communication). Despite these strategic 
investments, stock-outs of antiretroviral medicines remain a persistent problem in sub-
Saharan Africa,198 especially with respect to new regimens.199 Weaknesses in procurement 
and supply management are not confined to Africa or to HIV medicines but instead 
represent a systemic challenge that demands high-level and sustained attention. For example, 
in the Mekong region, where a rapid surge in malaria resistance has caused global alarm, 
fake or substandard anti-malaria medicines are common.200 Maintaining separate disease-
specific systems for procurement and supply chain management wastes money, reduces 
incentives for service integration within health systems and facilities, and siphons scarce 
funding away from needed systemic investments.
Comparable actions are needed to strengthen and sustain laboratory systems. Independent 
evaluators found that PEPFAR’s impact on national laboratory capacity has been 
“fundamental and substantial”.197 Investments by PEPFAR, the Global Fund, and other 
donors have resulted in the training of tens of thousands of laboratory professionals, the 
purchase of new laboratory equipment, and upgrading the degree of management and 
organisation in laboratory medicine, especially in sub-Saharan Africa.
Although HIV has served as a shot in the arm for many laboratory systems, these functions 
remain badly under-resourced. Maintenance of vertical funding streams for laboratory 
medicine undermines efforts to apply laboratory technology and skills across diseases. For 
example, although management of HIV and tuberculosis is critically linked, laboratory 
services for the diseases often remain distinct and unintegrated. This represents an important 
missed opportunity because certain laboratory tools, such as the nucleic acid diagnostic 
networks created to support early infant HIV diagnosis, have the potential to enable 
diagnosis of a range of diseases (Peter T, Clinton Health Access Initiative, personal 
communication).
Structural change and health in lesbian, gay, bisexual, transgender, and 
intersex (LGBTI) communities—In a singular achievement, the global HIV response 
has yielded new opportunities for gay and bisexual men and others in LGBTI communities 
to be recognised as citizens, rights holders, and beneficiaries of public health programmes in 
their own countries. Donor funding has played a pivotal part in supporting LGBTI 
communities to engage in HIV leadership and in developing programming in gay and 
bisexual men and other marginalized populations. Among 93 countries reporting the 
existence of HIV services for gay and bisexual in 2005–13, 67 countries said these 
programmes were wholly dependent on international funding.
Bringing an end to HIV exceptionalism risks rolling back this historic progress in 
recognising and responding to the health and related needs of LGBTI people. For example, 
replacing disease-specific and population-specific funding streams with general health-
system funding could jeopardise the sustainability of community-led organisations in the 
many countries whose governments have proven either indifferent or openly hostile to gay 
and bisexual men. Innovative models of service delivery, which communities of gay and 
bisexual men have developed in the face of stigma and discrimination, could well be lost.
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Universal health coverage offers new opportunities to right many of these wrongs associated 
with the longstanding underprioritisation of the health needs of LGBTI people. However, 
while coverage is expanded to all, irrespective of demographic status, health systems also 
must be transformed to respond to the diversity of the people they serve. This will require 
the routine collection and analysis of disaggregated data to understand health status in 
LGBTI sub-populations, to measure programme performance, and to assess LGBTI 
communities’ satisfaction with services.
Opportunities for integration: key conclusions of the Commission
In disease-specific and population-specific reviews, the Commission has identified 
numerous opportunities (both in the immediate term and longer term) for synergising HIV 
with the broader global health agenda and for advancing intersectoral action towards 
universal health access (table; panel 2).201
Integration of HIV and other health services: modelled scenarios
As indicated by the multiple domains in which integration of HIV and broader health, social, 
and structural approaches is warranted, the opportunities for integration are myriad. Actions 
to integrate HIV and global health aim to achieve win-win results, whereby both HIV-related 
and non-HIV-related health outcomes are enhanced in a manner that is cost-effective. 
Movements to integrate HIV into health systems will and should be incremental at the 
outset, with integrated approaches tailored to national conditions. Rather than attempt a 
rapid and wholesale transfer of vertical programmes to national health systems, initial efforts 
might focus on more fully integrating HIV with services to address other health issues (eg, 
sexual health, NCDs, tuberculosis). Especially for marginalised populations that are not well 
served by mainstream health services, early steps towards integration might focus on 
integrating HIV services with services that specifically serve these populations (such as 
harm reduction services in the case of people who use drugs).
Successful integration of HIV services with other health services requires an in-depth 
understanding of setting-specific factors that drive the potential effect of new programmes at 
a national level. Given the diversity of HIV epidemics and health systems, we studied the 
potential effect of HIV integration in five countries with different HIV epidemic profiles and 
health-system characteristics—thus requiring different approaches to integration of HIV 
with other health services (figure 13). In each country scenario, we estimated the population-
level effect of integration, not only in terms of HIV-specific outcomes but also in terms of 
potential effect on other health conditions. In select countries, we additionally estimated the 
cost-effectiveness of these programmes.
South Africa: mobile multidisease screening for HIV and NCDs
The world’s largest HIV epidemic is in South Africa, an upper-middle-income country, 
where an estimated 7·1 million people have HIV, and the prevalence of HIV infection is 18–
9%7 South Africa also has a burgeoning epidemic of NCDs. 30% of women aged 55–64 
years have diabetes,202 and the diabetes-specific mortality has beensteadily increasing since 
1997,203 reaching 3·6% of all deaths in 2012.204 Cardiovascular disease accounted for 
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18·5% of all deaths in South Africa in 2012,204 and an estimated 31·8% of South African 
adults have hypertension, the leading risk factor for cardiovascular disease.205 Altogether, 
HIV, diabetes, and cardiovascular disease accounted for 51% of all deaths in South Africa in 
2012.204 Although high levels of HIV diagnosis have been achieved in South Africa,206 only 
half of diabetes and hypertension cases have been diagnosed, and disease is seldom 
effectively controlled (figure 14). Platforms that integrate screening for these three diseases 
have the potential to address the urgent need for improved diagnosis of diabetes and 
hypertension.
Several mobile multidisease screening interventions have been piloted in South Africa207 
(figure 15) and other African countries.208,209 To assess the potential effect and cost of 
introducing a mobile screening service for diabetes, hypertension, and HIV in South Africa, 
we extended an HIV model that was previously developed for South Africa, to incorporate 
diabetes and hypertension screening (panel 3). The model estimates that if such a 
multidisease screening programme were introduced in 2018–28, and reached 10% of South 
African adults each year, the programme would diagnose 492 000 new HIV cases, 1·21 
million new diabetes cases, and 6·35 million new hypertension cases. Expressed as a fraction 
of individuals screened, the proportion newly diagnosed is expected to be lowest in the case 
of HIV and highest in the case of hypertension (figure 14). The total number of new treated 
HIV, diabetes, and hypertension cases would be expected to increase by 197 000, 543 000, 
and 2·1 million, respectively. As a result of the increase in HIV diagnosis and treatment 
rates, the incidence of adult HIV infection is expected to decrease by 3·5% in 2018–28, 
which is equivalent to 69 000 infections averted.
Kenya: screening for HIV with hypertension and diabetes
Kenya has the joint fourth largest HIV epidemic in the world, with 1·6 million people living 
with HIV in 2016.1 Although the prevalence of HIV in adults (5·4%) is lower than in South 
Africa (18·9%),1 the proportion of HIV that remains undiagnosed (30%)214 is higher in 
Kenya than in South Africa (13%). As is the case across sub-Saharan Africa, Kenya is 
experiencing an increasing burden of NCDs, which account for 27% of all deaths and 50% 
of hospital admissions.215 Much of this increase can be attributed to lack of screening and 
early detection of NCDs, which in turn leads to late diagnosis and poor treatment outcomes. 
For example, 56% of people in Kenya have never had their blood pressure measured, and 
only 22% of individuals with increased blood pressure or hypertension diagnosis report 
taking treatment.215 These enormous gaps in screening and treatment of NCDs are occurring 
in the context of an overwhelmed health system and an HIV epidemic that has yet to be 
brought under control.
A modelling scenario for integrated screening for HIV, hypertension, and diabetes in Kenya 
is shown in panel 4. At baseline and in the absence of additional intervention, the incidence 
of HIV infection in Kenya is estimated to decrease by 13% in the next decade. The 
integration scenario models a gradual increase in HIV screening and coverage of ART over 
time, reaching a population-level coverage of 78% in 2028. This corresponds to an 
additional 4 117 912 person-years on ART in the next decade. With this intervention, the 
number of new HIV infections is projected to decrease by 44% by 2028, corresponding to 
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216 655 new infections and 244 374 AIDS deaths averted (figure 16). Sensitivity analyses of 
ART uptake suggested that even with only 40% treatment initiation, the integration scenario 
would reduce the incidence of HIV infection by 23%. Given the longer life expectancy of 
HIV-positive individuals receiving ART, the intervention results in only marginal 
improvements in HIV prevalence (1·4% reduction by 2028), despite the substantial 
reductions in new infections.
Pairing NCD screening with HIV testing has important effects on the continuum of NCD 
care. Immediately after the first year of screening campaigns, treatment in the intervention 
communities increased from 10% to 47% for diabetes and from 8% to 27% for hypertension. 
First year effects would be less dramatic at the national level, but the national care cascades 
for hypertension, diabetes, and HIV will continue to improve as more communities are 
covered under this programme. Over the ensuing decade, this integrated screening and 
linkage-to-care intervention is projected to identify 686 000 individuals with previously 
untreated diabetes and 7·57 million individuals with previously untreated hypertension.
The per-person costs of the community health campaign are estimated at $21·03 for 
community census and HIV testing and $1·19 for hypertension and diabetes screening, all 
valued in 2016 $US. With an estimated 4·51 million individuals aged 15 years or older who 
were screened in 2018, total costs for community mobilization would be $56·8 million for 
HIV testing and $3·2 million for NCD testing. In 2018, the number of people receiving ART 
would increase by 67 000 at an additional cost of $16·9 million, and by 2028, 659 000 
additional people would receive ART for $346·3 million in additional treatment costs 
(assuming no further price reductions for ART). Through 2028, the HIV-related components 
of the community health campaign would avert 6·5 million DALYs at a discounted cost of 
$1480 million, equivalent to $227 per DALY averted, making the intervention highly cost-
effective relative to 2016 GDP per capita of $3155.
We estimate that 590 000 individuals with moderate or high blood pressure not currently on 
treatment will be identified in 2018. Assuming an uptake of hypertension treatment at 
23%215 and discounted incremental lifetime health-care costs of $149 and $486 for 
moderate-risk and high-risk hypertension treatment, respectively, the hypertension screening 
and treatment would avert 160 000 DALYs at a cost of $37·2 million, corresponding to $232 
per DALY averted. Over the 10-year modelling scenario, the population would increase, as 
would the costs and benefits, reaching $49·8 million and 215 000 DALYs averted in 2028.
Assuming a prevalence of 2·2% for diabetes in adult Kenyans,202 we estimate that blood 
glucose screening in conjunction with the HIV community health campaign would identify 
53 000 individuals with diabetes at a marginal cost of $54 per case identified, with this cost 
jointly shared by hypertension screening. With standard glycaemic control for individuals 
with diabetes, the cost per DALY averted is about $944.218 As with the HIV-related 
components, the hypertension and diabetes components are estimated to be highly cost-
effective.
From a costing perspective, integrated programmes will probably be cost-effective with 
respect to both HIV-related and NCD-related outcomes. From a policy perspective, in the 
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context of limited resources at the national level and competing interests for allocation of 
available funding to different health sectors, integration of services for HIV and NCDs offers 
a promising solution to diagnose HIV and NCDs. Nonetheless, increased diagnosis will 
probably lead to increased demand for health-care services in both Kenya and South Africa 
and will require substantial resources to meet the demand.
Nigeria: integration of HIV with reproductive health services
With more than 3·2 million people infected with HIV, Nigeria has the second largest HIV 
burden in the world. Unlike South Africa and Kenya, where more than 95% and 80% of 
eligible women receive prevention of mother-to-child transmission (PMTCT) services, 
respectively,1 PMTCT coverage in Nigeria has stagnated at 30%, resulting in an estimated 
75 000 new infant HIV infections per year.219 Similarly, only 15% of Nigerian women aged 
15–49 years use contraception for limiting and spacing of births. On average, a Nigerian 
woman gives birth to 6·5 children in her lifetime. As 16% of currently married women have 
an unmet need for family planning services, linking all married women who wish to space or 
limit their children to contraceptives would increase the prevalence of contraceptive use to 
31%.220
The modelling scenario for integration of HIV and reproductive health services in Nigeria is 
shown in panel 5. In the absence of additional intervention, the baseline model estimates a 
37% increase in the number of women of reproductive age in the next decade (2018–28) 
because of population growth, resulting in a growing need for family planning services in 
Nigeria. Expansion of contraceptive use to 31% was estimated to result in a 15·5% reduction 
in the total fertility rate (ie, from 6·5 children per woman at baseline to 5·49 children per 
woman in 2028; figure 17). This reduction in fertility would avert more than 8 million 
cumulative unintended pregnancies between 2018 and 2028 when compared with a baseline 
level of contraceptive use of 15%. Increasing PMTCT coverage to 90% of HIV-positive 
pregnant women in Nigeria by 2023 is estimated to reduce the number of infants acquiring 
HIV by 56% (figure 17), averting more than 237 500 vertical HIV transmissions 
cumulatively in the next decade. Expansion of PMTCT services along with family planning 
resulted in a further estimated 12% reduction in HIV incidence at the national level, which is 
equivalent to averting more than 295 500 new HIV infections by 2028 (figure 17) and a 
3·5% reduction in population-level HIV prevalence.
Increasing access to PMTCT would require $31·3 million in 2018, which includes $17·3 
million in screening costs and $14·0 million in PMTCT costs. With full scale-up in 2023, 
$172·2 million would be required to identify and deliver PMTCT to an additional 142 000 
HIV- positive pregnant women. Although the number of women receiving PMTCT would 
decrease through 2028, the costs would increase slightly to $181·0 million because of the 
larger number of pregnant women requiring screening as the prevalence of HIV decreases. 
From 2018 to 2028, the scale-up of PMTCT would avert 8·6 million DALYs at a cost of 
$169 per DALY averted and, compared with the GDP per capita of $5861 in 2016, would be 
highly cost-effective.
An increase in contraceptive use from 16% to 31% would require an additional investment 
of $4·8 million in 2019, increasing to $27·4 million in 2023 with greater coverage and 
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population growth, and increasing further to $32·3 million in 2028 with continued 
population growth. About 90% of the increased investments needed for scaled-up 
contraceptive services would be offset by maternal and infant health-care costs averted 
through family planning. 484 000 DALYs averted per year in 2019 would increase to 3·2 
million DALYs averted per year in 2028, with a total of 22·9 million DALYs averted. 
Increased access to family planning is highly cost-effective and approaches the cost-saving 
threshold, with a net cost of about $0·95 per DALY averted.
These results suggest that substantial improvements can be achieved by integrating HIV and 
reproductive health services for women in Nigeria, averting, in the case of HIV, more than 
230 000 new infections in the next decade. A crucial first step for ensuring the successful 
integration of HIV with reproductive health services is addressing the underlying 
weaknesses of the existing health services in Nigeria because more than a third of pregnant 
Nigerian women do not attend antenatal care services during pregnancy,224 with especially 
low coverage in poor, rural, currently married, and less educated populations. Integration can 
aid in expanding the coverage of family planning services in Nigeria, which in turn can avert 
a large number of unwanted pregnancies and unsafe abortions.
India: Integrated management of HIV and sexually trainsmitted infections for men who 
have sex with men (MSM) and female sex workers (FSW)
With more than 2 million people with HIV and an estimated 62 000 AIDS-related deaths in 
2016, India has the third largest HIV epidemic in the world.1 Although most HIV 
transmissions are driven by heterosexual sex (accounting for 87% of new infections in 
2015), the epidemic is concentrated in high-risk groups, particularly in FSW and their 
clients, MSM, and people who inject drugs in some sub-national settings. In 2016, an 
estimated 2·2% of FSW in India had HIV, although there are considerable geographic 
variations, with a prevalence in this population as high as 17·9% in Maharashtra and 13·1% 
in Manipur in 2013. Similar variations are reported for other sexually transmitted infections, 
with the prevalence of syphilis ranging from 3·1% to 51·0% for FSW and from 3·5% to 
28·0% in MSM and transgender people.225
India is committed to the prevention and control of epidemics of sexually transmitted 
infections and HIV. The Avahan initiative is estimated to have averted 202 000 HIV 
infections in 4 years.226 Respondent-driven sampling has been used to engage MSM and 
people who inject drugs in testing services for sexually transmitted infections and HIV in 
India.227 In addition to expanding the reach of these screening and prevention programmes, 
integration of sexually transmitted infections and HIV can also facilitate linkage to, and 
engagement in, HIV care through a combination of medical, social, and economic 
interventions targeting key populations. We applied the Spectrum model to estimate the 
epidemiological and economic effect of such an approach on outcomes related to HIV and 
sexually transmitted infections in MSM and FSW in India (panel 6).
The integrated intervention is projected to gradually increase coverage of ART in the next 5 
years, reaching coverage of 73% of MSM (compared with 43% at baseline) and 81% of 
FSW (compared with 29% at baseline). This corresponds to an additional 1 180 000 person-
years on ART in the next decade. Through this intervention, the number of new HIV 
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infections in MSM is projected to fall by 34% by 2028, corresponding to 43 000 new 
infections averted (figure 18), and 59 000 AIDS-related deaths will be averted. Given the 
projected rapid decrease in HIV incidence in FSW at baseline, the intervention is estimated 
to reduce HIV incidence only marginally (1·6% reduction in 10 years) but AIDS-related 
deaths substantially (by 81%), averting 6200 deaths in FSW. At a national level, this 
intervention reduces the number of new transmissions in the population by 7%, averting 51 
000 new infections and 81 000 AIDS-related deaths in the next decade. In sensitivity 
analyses with 40% (vs 81%) uptake of ART, HIV incidence was roughly halved, with HIV 
incidence falling by 17% in MSM, by 0·4% in FSW, and by 3–2% at a national level.
Implementation of PrEP will further improve the epidemiological outcome, although the 
extent of PrEP-related benefits is limited by the preventive effects of expanded ART 
coverage. For example, provision of PrEP at a low-coverage or high-coverage level 
(corresponding to more than 11·1 million and 33·6 million person-years of PrEP from 2018 
to 2028, respectively) will avert 6800 and 20 000 additional new HIV infections in MSM 
and FSW compared with ART scale-up alone. With respect to other sexually transmitted 
infections, the integrated HIV-syphilis programme is projected to diagnose and treat more 
than 510 000 cases of syphilis in FSW (5·8% prevalence) and MSM (3·5% prevalence) in 
2018 alone. The number of cases detected and treated in subsequent years will depend in 
part on the rate of infection and reinfection in individuals who were previously treated.
In the intervention scenarios, recruitment and HIV testing and referral costs would increase 
from $34·1 million in 2018 to $190·4 million in 2028. With 81% uptake of ART by 
individuals who are diagnosed, the number of people receiving ART would increase over the 
baseline by 55 000 in 2018 and by 107 000 in 2028. Excluding PrEP, the programme of 
testing and reatment would be highly cost-effective, averting 2·7 million DALYs at $656 per 
DALY averted (per-capita GDP of $6571 in 2017), with an incremental cost of $1797 
million over the base-case cost of $1·315 million. Neither of the PrEP scenarios (10% or 
30% coverage) would be cost-effective, with an incremental cost of $21 531–58 812 per 
DALY averted compared with the no-PrEP scenario.
The addition of syphilis screening and treatment to the HIV testing and treatment (but no-
PrEP) scenario would probably be highly cost-effective. In 2018, the programme would test 
1·68 million individuals and diagnose and treat 76 000 cases at an incremental cost of $6·6 
million. At an estimated 0·64 DALYs per prevalent case, we estimate that this scenario 
would avert 49 000 DALYs in the first year at $135 per DALY averted.
Our results suggest that the modelled interventions would lessen the burden of HIV and 
syphilis infection in MSM and FSW in India. Increasing the coverage of ART in MSM to 
54% would avert substantial numbers of new HIV infections and AIDS-related deaths. 
Further addition of PrEP can provide marginal improvements in HIV-related outcomes, 
although the population-level implementation of PrEP in these populations in India is not 
cost-effective. As suggested by previous studies, PrEP should be tailored to high-risk 
populations who stand to benefit the most from it. On the other hand, despite assuming a 
higher level of achievable coverage in FSW (up to 90%), similar programmes resulted in 
smaller improvements to HIV incidence over time in this population, primarily stemming 
Bekker et al. Page 45
Lancet. Author manuscript; available in PMC 2019 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
from the decreasing prevalence of HIV in FSW in India. Integrated programmes provide an 
opportunity for mass screening and treatment of other sexually transmitted infections, 
including syphilis. Even ignoring the potential effect for averting future syphilis 
transmissions and reducing the transmissibility of HIV infection in coinfected cases, the 
integrated programme was cost-effective.
Our results for these scenarios in India are limited by several restricting assumptions. First, 
we excluded the existing geographical heterogeneities in patterns of the prevalence of 
sexually transmitted infections and HIV in key populations in India (as evident by a wide 
range of reported HIV prevalences in MSM, ranging from 2·5% in Tamil Nadu to 14% in 
Andhra Pradesh in 2016), which can have important implications for the estimated effect 
and costs of integrated programmes in different part of the country. Future research could 
build on our findings by investigating the effect of integration in various Indian cities and 
states representative of different epidemiological profiles and health-system infrastructures. 
Further-more, our simplified approach to estimating the effect of intervention on sexually 
transmitted infections is limited by restricting assumptions that might underestimate the 
effect of interventions on the sector. Future studies applying transmission models of HIV-
sexually transmitted infection co-epidemics in India might provide more representative 
estimates of epidemiological outcomes.
Russia: integrated harm reduction and ART for people who inject drugs
An estimated 1% of the Russian population has HIV, but the prevalence of HIV is much 
higher in people who inject drugs, with city-level estimates for this population ranging from 
3% to 64%. 233 Several regions in the Ural and Siberian Federal Districts have the highest 
incidences of new HIV diagnoses in the country, most of which are in people who inject 
drugs.76 People who inject drugs in Russia are also at high risk of overdose (estimated at 2 
overdoses per 100 person-years).234
Although harm reduction and HIV treatment services would clearly benefit the country’s 
estimated 1·88 million people who inject drugs, considerable barriers prevent these services 
from being scaled up. Non-naltrexone MAT remains illegal, despite evidence that it reduces 
HIV transmission risk,235 fatal overdose,236 drug-related criminal behaviour,237 and 
discontinuation of ART;238 and NSPs are legal but badly underfunded, providing on average 
only 1–3 syringes per person who injects drugs annually.115 Coverage of ART in people who 
inject drugs is low,239 with evidence of denial of therapy to active users of drugs in some 
settings,240 and 2017 Russian clinical guidelines recommend possibly delaying treatment 
initiation in patients with evidence of severe drug addiction,241 which could act as a barrier 
for the scale-up of ART in people who inject drugs.
We examined the effect of policy changes enabling the expansion of integrated harm 
reduction and HIV services on HIV and fatal overdose among people who inject drugs in 
two Russian settings. A dynamic transmission model of HIV among people who inject drugs 
(panel 7) was developed to assess the effect of scaled-up harm reduction (NSP or non-
naltrexone MAT, or both), alone or integrated with scaled-up ART for people who inject 
drugs. For illustrative purposes, we modeled two different HIV epidemic settings (figure 
19): (1) Omsk, a major city in the Siberian Federal District with evidence suggestive of a 
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growing epidemic; and (2) Ekaterinburg, Russia’s fourth largest city located in the Ural 
Federal district with a stable and high-prevalence epidemic in people who inject drugs.
Removal of structural and funding barriers in harm reduction provision could have a 
substantial effect on both HIV and fatal overdose. Expanding high coverage NSP to 50% of 
people who inject drugs could avert 36% (2·5–97·5th percentile 15–51%) and 23% (7–33%) 
of new HIV infections in people who inject drugs in the next decade in Omsk and 
Ekaterinburg, respectively (figure 19). A legal change allowing non-naltrexone MAT would 
avert both HIV infections and prevent fatal overdose. Scaling up non-naltrexone MAT to 
50% coverage could avert 36% (2·5–97·5th percentile 21–49%) and 21% (11–29%) of HIV 
infections in Omsk and Ekaterinburg, respectively, and prevent about 32% (26–37%) of fatal 
overdoses in 10 years in Omsk and Ekaterinburg. About half the effect on HIV and 
overdoses would be achieved if MAT were only scaled-up to 25%. In combination, scale-up 
of MAT and NSP at 50% coverage could avert 48% (2·5–97·5th percentile 28–60%) and 
33% (23–39%) of HIV infections in people who inject drugs at 10 years in Omsk and 
Ekaterinburg, respectively.
Scale-up of combination MAT plus NSP to 50% of people who inject drugs and integrated 
ART (recruiting HIV-infected people who inject drugs in harm reduction at three times the 
current recruitment rates) would avert 53% (2·5–97·5th percentile 40–65%) and 36% (25–
45%) of new HIV infections in 10 years in Omsk and Ekaterinburg, respectively.
Given the paucity of existing HIV prevention services for people who inject drugs, the 
economic implications of the expansion scenarios described are uncertain. However, 
methadone is cost-effective in neighbouring Ukraine242 and Kazakhstan,243 at an estimated 
annual cost of US$250–415 per person who injects drugs (2017 US$). During the period 
when the Global Fund invested in HIV programmes in Russia, the cost per needle exchanged 
in the country was $0·38.244 Scaling up MAT and NSPs to 50% of the 1·88 million people 
who inject drugs in Russia could cost $333–521 million annually. Additionally, the cost of 
ART regimens varies from $3050–4290 per year in Russia,245 and modelling has predicted 
ART provision for people who inject drugs would be cost-effective in Russia.
Our work supports findings from previous studies, which indicate that removing policy and 
programmatic barriers and expanding HIV and harm reduction services to people who inject 
drugs in Russia would have a substantial effect on HIV,246 and reveals marked benefits in 
preventing fatal overdose. Our analysis does not take into account likely additional benefits 
that scaled-up harm reduction services would have on preventing HCV transmission or 
recidivism, which are likely to be substantial, as an estimated 69% and 40% of people who 
inject drugs in Russia have a history of HCV infection and incarceration, respectively.
178,247,248
These modelling exercises show multiple health benefits that could be achieved through 
integrating services for HIV and other health conditions, and they also highlight the crucial 
need for setting-specific approaches to integration. In settings such as Kenya and South 
Africa, with generalised HIV epidemics and increasing burden of underdiagnosed and 
undertreated NCDs, integrated community-based screening could yield substantial benefits 
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in identifying and treating hypertension, diabetes, and HIV. The realisation of such benefits, 
however, will be limited by the capacity of the health-care system to provide appropriate 
treatment. In settings like Nigeria with low antenatal care coverage and substantial mother to 
child HIV transmission, integration of PMTCT and family planning services could reduce 
HIV infections in infants and in the population as a whole as well as prevent unintended 
pregnancies. Increasing PMTCT coverage will require both access to and uptake of care. 
The former might require substantial infrastructure and human resources investments, and 
the latter could benefit from scale-up of peer support or congregation-based interventions.
In countries with concentrated epidemics in FSW and MSM, integrating testing and 
treatment for sexually transmitted infections and HIV should be considered. Modelling in 
India suggests that this approach would be cost-effective in addressing HIV and syphilis 
infections in both sex workers and MSM. Although we have modelled a streamlined 
approach, a more comprehensive intervention such as Avahan could prove more cost-
effective. In some countries, few or no services are available for integration for highly 
affected populations. For example, in Russia, where there is a high concentration of HIV in 
people who inject drugs, the harm reduction, drug treatment, and HIV services for this 
population are either illegal or reach few in need. As such, there is an urgent need in Russia 
first for legal changes and capacity building to provide basic health services for people who 
inject drugs, ideally in an integrated programme that could reduce HIV, HCV, fatal overdose, 
and mass incarceration. Future work should consider the optimal integration strategy in each 
country based on HIV epidemiology and the health-care system, and models of integration 
will be improved through increased understanding of barriers and facilitators of integration 
and will depend on how well different integration scenarios can achieve economies of scope 
and scale. The potential benefits of integration are substantial, but they are only realisable 
with the bridgingof now-siloed health-care strategies.
The future of global health and HIV: governance and financing
Capturing and sustaining the benefits of a more integrated approach to HIV and global 
health, as demonstrated in the Commission’s modelling studies, will demand governance 
approaches that enable the world to give health the priority it deserves. Additionally, 
substantial, new, and reliable financing will be necessary to lay the foundation for 
sustainable health for all.
Governance for sustainable global health
The path towards a robust governance system for global health suitable for the era of 
sustainable health and development will inevitably be complicated, involve diverse 
stakeholders, and require honest dialogue about the strengths, weaknesses, and value added 
of all actors that have a role in health governance. For the new era of global health solidarity, 
a review of governance architecture is warranted. New institutional frameworks or 
approaches might be needed to elevate health as a central global priority and to usher into 
place comprehensive, integrated, and people-centred health systems that provide universal 
health access. To this end, the Commission urgently calls for an independent effort, 
authorised by an appropriate resolution of the UN General Assembly, to outline new 
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institutional architecture and arrangements to carry forward the new era of global health 
solidarity envisaged by the Commission. A similar approach has been used before, when a 
UN resolution authorised the deliberative process that resulted in the closure of the WHO 
Global Programme on AIDS and the launch of UNAIDS.84 As a key component of the work 
of this independent governance review, actionable recommendations should be developed to 
make HIV governance less duplicative and costly and optimally accelerate progress toward 
ending the pandemic.
HIV and health governance
The HIV response arguably has the best developed mechanisms for governance of any 
aspect of the global health agenda. The institutional governance structure for HIV was 
developed rapidly, beginning in the mid-1990s at the global level, in response to the 
recognition of HIV as a global health emergency. Key actors in the pluralistic HIV 
governance approach include national health ministries, participatory national coordinating 
bodies (eg, national and provincial AIDS councils, country coordinating mechanisms), 
international governance bodies (eg, UNAIDS Secretariat and Cosponsors, including WHO), 
key donors (eg, Global Fund, PEPFAR, Bill & Melinda Gates Foundation, and other 
philanthropic entities), and organisations that focus on specific HIV priorities and functions 
(eg, Unitaid for market-shaping, Medicines Patent Pool for the issuance of voluntary 
licensing).
HIV governance includes elements that can inform the evolution of global health governance 
more generally, including its engagement of civil society and affected communities, 
institutional emphasis on a multisectoral response, and ethos of mutual accountability for 
achievement of concrete targets. HIV remains unusual within the global health field with 
respect to the extent of its formalised engagement with civil society (figure 20). Global 
health governance will be more responsive, effective, and politically potent if it includes 
strong participation from diverse non-governmental stakeholders. The greater integration of 
affected communities in global health governance, should it occur, will be one of the lasting 
legacies of HIV activism.
However, the HIV experience also offers warning signs, as governance of the HIV response 
over time has become bloated and overly costly. The elaborate mechanisms for governance 
of the HIV response have not prevented a premature withering of commitment to the HIV 
fight. In addition to clearly outlining an overarching global health governance architecture, 
the independent panel proposed by the Commission should also examine how best to ensure 
that HIV governance is fit for the purpose of meeting current challenges and galvanising a 
sustainable response for the long term. Making HIV governance leaner, focusing governance 
on the overriding challenge of rebuilding political support and financing for HIV, and 
reviving African solidarity and leadership on HIV will be pivotal to hopes for rejuvenating 
the response.
Although efforts to strengthen governance of certain aspects of global health are growing, as 
reflected, for example, in the Third High-Level Meeting on NCDs planned at the UN in 
2018, the gap in governance between HIV and non-HIV-related health issues is considerable. 
Neither NCDs, maternal and child health, nor any other single disease, for example, has 
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advocacy benefits, partnership cultivation, and focused governance structure that is 
comparable to what UNAIDS brought to the HIV response. By contrast with HIV, key 
weaknesses of the global fight against cancer and other NCDs include the lack of strong 
global leadership and an inclusive social movement.249 The new governance approach for a 
new era of global health solidarity must include both overarching governance structures that 
address health-system weaknesses and promote comprehensive approaches that integrate 
services for diverse health conditions as well as sufficiently resourced and high-visibility 
disease-focused advocacy and governance structures to drive progress against the leading 
causes of death and disability (eg, cancer, cardiovascular disease, maternal and childhealth, 
tuberculosis).
The multidimensional governance structure developed for HIV includes key functions that 
will be required to ensure sustainable health for all. For example, the Global Fund is a highly 
successful platform for pooling resources for results-driven national programmes for HIV, 
tuberculosis, and malaria. Likewise, outside the HIV arena, GAVI, the Vaccine Alliance has 
had a pivotal role in increasing the rates of childhood immunisation250 by pooling and 
distributing resources for vaccination programmes in resource-limited settings. To accelerate 
health access and achieve the ambitious health aims of SDG 3, one or more similar 
mechanisms will be needed to mobilise, pool, and distribute resources for health systems 
strengthening, universal and equitable access to health commodities, and programmes to 
address priority health conditions such as NCDs and sexual and reproductive health.
Market-shaping measures will be needed to facilitate access to affordable medicines, 
vaccines, and diagnostics. In the case of HIV, the Medicines Patent Pool issues voluntary 
licenses for the generic manufacture of priority medicines, whereas Unitaid undertakes 
market-shaping interventions to enhance the affordability and uptake of essential 
interventions. To achieve worldwide expansion of access to health commodities to treat other 
leading causes of deaths, these market-oriented functions must extend well beyond HIV. To 
date, the voluntary licensing route has been used for HIV medicines and recently for direct-
acting antivirals for HCV but not for medicines to treat cancer, hypertension, diabetes, or 
other diseases.
A sound health system is necessary but not sufficient for ending the HIV epidemic. 
Although opportunities for synergies and greater integration must be seized, categorical 
programmes and a dedicated governance system will remain essential if the world hopes to 
make good on its many HIV commitments.
Towards sound governance for sustainable health: key principles
Governance mechanisms must ensure that communities and broader civil society are fully 
engaged as partners in the conceptualisation, implementation, and monitoring of people-
centred health systems. Health governance must strive for equity in access to global health 
goods and in health outcomes. Ushering in an era of genuine global health solidarity will 
demand a shared understanding of global health as a common enterprise, with institutional 
governance arrangements that are inclusive, democratic, and take into account the 
perspectives of all stakeholders.
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Governance mechanisms for health must be sufficiently resourced, transparent, and 
accountable. Health governance should be multidisciplinary to ensure appropriate attention 
to social and structural factors and to promote integrated and coordinated approaches to 
multiple health challenges. Governance for health must be forward-looking and build 
capacity at national, global, and regional levels to anticipate and respond to future problems 
such as health emergencies or national transition from eligibility for international assistance. 
Transitions away from international support must be undertaken over a reasonable period of 
time (at least 10 years), and flexibility in transition approaches will be essential, enabling 
course corrections if and when problems arise (such as the collapse of community service 
systems for marginalised groups). Eligibility for international assistance should continue for 
countries with limited domestic capacity, heavy disease burden, and high-prevalence, high-
incidence settings or populations.
Consistent with the vision of sustainable health for all, global health governance must ensure 
prioritised attention to the most susceptible and marginalised people. Global health 
governance must reflect and promote principles of human rights and gender equity. The new 
era of global health solidarity will demand governance mechanisms that elevate scientific 
evidence over ideology. Effective health governance evinces a willingness to speak hard 
truths when necessary.
Effective health governance functions as a faithful steward of public resources, 
implementing measures to protect against corruption, diversion of resources, and conflicts of 
interest. Effective health governance also inevitably depends on sound governance more 
generally, underscoring the need for countries to adhere to principles of democracy, open 
societies, inclusive and participatory processes, transparency, and accountability.
Financing for sustainable global health
Achieving universal health coverage will require substantial resources over and above 
amounts presently spent on health.251 For both HIV and global health generally, a 
continuation of current trend lines in financing will leave the world without sufficient 
resources to achieve the ambitious health targets of SDG 3.5,252,253
A new era of global health solidarity is needed, augmenting and fully synergising the 
contributions of each essential financing sector (eg, national governments, the international 
community, and the private sector) and continually reinforcing health investments as central 
to the international development agenda. Key to this era of global health solidarity will be 
rapid creation of a reliable, sustained mechanism for the equitable distribution of global 
public goods supported by global-level mechanisms to generate and pool resources.
As the decision to allocate resources inevitably reflects political choices, a political sea 
change is needed if the financing required to control communicable diseases and to 
effectively manage NCDs is to be mobilised. Drawing on experiences from the 1990s and 
early 2000s, when the world was jolted out of its early and lethargic response to the HIV 
epidemic, the HIV community must urgently join together to focus the world’s attention on 
the very real risk that we will lose the fight against HIV without major new investments. 
African leaders, in particular, must become broadly re-engaged in rejuvenating the HIV 
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response because failure risks undermining the sustainable development agenda. Together, 
the HIV community and the broader global health field must undertake a comprehensive 
advocacy effort to position health as central to the broader global development agenda.
Domestic resources, which already finance most of health spending in LMICs, must serve as 
a cornerstone of financing in the era of sustainable health.254 Health spending, both per 
capita and as a share of GDP, is increasing in LMICs, increasing faster than the economy as 
a whole in the past 15 years.254 However, per-capita amounts spent on health in some 
LMICs are too low to deliver even the most basic package of health services,255 and the 
failure of most African countries to meet the Abuja Declaration target for health spending 
highlights the need for greater domestic investments and political support for health. 
Economic growth offers an opportunity for many LMICs to increase investments in health,4 
but national leaders must demonstrate sufficient political will to allocate these dividends to 
health services. A recent analysis by the Global Burden of Disease Health Financing 
Collaborator Network4 found per-capita health spending in Bangladesh and Pakistan would 
roughly triple and double, respectively, were these countries to allocate towards health the 
share of national budget spent by similarly situated countries that place greater priority on 
health. Realisation of the vision of sustainable health for all will require LMICs to dig much 
deeper into their own pockets, and the World Bank and regional development banks must aid 
by expanding incentives to invest in health. To maximise domestic financing for health, 
systematic efforts are needed to avoid inefficiencies linked to the diversion of scarce 
resources through rent-seeking, clientelism, and corruption and to increase the 
accountability of national and subnational governments.
Universal health coverage can aid in off-loading certain health-related costs from the public 
sector and better enable public programmes to target services for the most susceptible 
communities. Although categorical HIV funding will remain essential for the foreseeable 
future to rejuvenate the response, funding for HIV programmes over time should 
progressively be integrated into broad-based social insurance systems, pooling resources 
through prepayment mechanisms, and innovative funding methods will be needed to 
incentivise integrated and multidisease approaches.
Careful planning and bridge funding are essential for an effective transition from donor 
dependence to national funding. However, the reality for the foreseeable future is that many 
countries, irrespective of whether bridge funding is available, are unlikely on their own to 
finance programmes that benefit marginalised populations that are politically powerless and 
that, in some cases, are subject to official harassment, institutionalized discrimination, and 
criminalisation. Both for HIV and for other priority health issues, the international 
community must continue to support essential prevention and treatment programmes for 
populations that would otherwise be left behind.
In addition to increased domestic financing, the new era of global health solidarity will 
require more, not less, engagement of the international community to foster collective 
action. In particular, robust international support for health will be essential to fund public 
goods, address cross-border health issues, and address health needs in low-income countries, 
where per-capita health spending, fiscal space, and health-system capacity will remain 
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limited.4,252 Africa accounts for the overwhelming majority of low-income countries that 
will continue to need extensive international health assistance.
The pivotal role of international donors in jump-starting the global HIV response has been 
widely heralded, but the reality is that high-income countries remain parsimonious with 
respect to global health and development assistance. Although developed countries have 
pledged to allocate 0·7% of gross national income to development assistance, in 2015, only 
six countries (Denmark, Netherlands, Norway, Luxembourg, Sweden, and the UK) reached 
this target.256 Official development assistance for health is projected to increase only 
marginally through 2030,4 and concern with recent reductions in international HIV 
assistance is growing.
Renewing the engagement of the international community on health issues will require new 
thinking and prioritisation by international decision makers. The growth in antimicrobial 
resistance257 and increasing concerns about the global capacity to respond to health 
emergencies are reminding international donors of their own stake in having strong and 
durable health systems in place in all countries. New political leadership in countries such as 
Canada, France, and South Africa offers opportunities to revive political support for global 
health.
Consistent with the Commission’s findings, financing efforts in the new era of global health 
solidarity must achieve two aims: follow through on commitments made on HIV and 
mobilise sufficient resources to build strong, durable and people-centred health systems; and 
achieve universal health access. A robust and well funded Global Fund will be essential to 
hopes for achieving major progress in reducing new cases of HIV, tuberculosis, and malaria 
and associated mortality from all three diseases, and similar mechanisms will be needed to 
finance health-systems strengthening and service integration and to focus efforts on 
preventing leading global causes of death.
The USA is by far the largest single donor for health assistance, although in other countries 
such as the UK, the proportion of GDP devoted to health assistance is greater than the USA.
258
 Although the Trump administration has proposed major reductions in international health 
assistance, it is heartening that a bipartisan coalition in the US Congress has rejected these 
proposed cuts and confirmed US leadership on global health. In the omnibus budget 
approved in March, 2018, for the fiscal year 2018, Congress provided 34% more funding for 
global health assistance than requested by President Trump, holding steady funding for 
PEPFAR and the Global Fund and increasing appropriations for global health security. The 
US Government should maintain support for PEPFAR as a singular contribution to global 
health and wellbeing. In particular, US decision makers should move beyond the singular 
focus on achieving epidemic control in its 13 priority countries, especially as feared funding 
cuts to PEPFAR have not materialised. As a shared global responsibility, financing for health 
will require greater engagement by the EU and cultivation of major new donors such as 
China.
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The future of global health and the HIV response: recommendations for 
sustainability
Creating people-centred health systems that ensure universal access to essential health 
services will demand concerted action by the entire global community. Only a genuine 
global movement, engaging diverse communities, linking together the HIV community and 
the global health field, and uniting multiple sectors in a common undertaking to improve the 
health and wellbeing of all people can realise the vision of sustainable health for all. 
Towards realisation of this vision, the Commission offers the following recommendations 
for immediate action.
1. The world must take immediate steps to rejuvenate the HIV response and follow 
through on its HIV-related commitments
All HIV stakeholders must join together to revitalise the HIV response, recognising both the 
urgency and the long-term nature of the global fight against HIV. Towards averting a 
potential resurgence of the epidemic, the reduction in HIV categorical funding, including 
major new investments by domestic governments and international donors, must be reversed.
HIV prevention must be revitalised and brought to scale. Whereas redoubling efforts to 
maximise the preventive and therapeutic benefits of ART through achievement of the 90–
90-90 benchmarks, national governments, international donors, and HIV advocates must 
place much higher priority on primary HIV prevention to avert a resurgence of the epidemic. 
Communities should be resourced to lead prevention efforts, and stronger, prioritised 
investments in research are needed to accelerate progress towards the development of a 
preventive vaccine and a cure for HIV.
2. HIV should be carefully and strategically integrated within primary care and the 
broader global health agenda, with the scale and pace of integration geared to national 
and subnational circumstances and the needs of the populations in greatest need of HIV 
services
Immediate efforts are required to integrate HIV services with services for diseases that 
clearly overlap or are closely linked with HIV, and strengthened integration of contraceptive 
services, maternal child heath, and women’s sexual health and reproductive rights, which is 
cost-saving and of vital importance to women’s health, is urgent for successful control of 
perinatal transmission of HIV. Co-located and client-centred primary care services (one-stop 
shopping) should be scaled up. Effective integration will involve both the integration of HIV 
interventions in mainstream primary care and other service systems as well as the leveraging 
of HIV service systems for the co-located integration of other health services.
Effective integration of HIV with broader health systems is only possible if key defining 
features of the HIV response are preserved and mainstreamed; these include a respect for 
human rights and gender equality, sufficiently resourced participatory mechanisms for 
community inclusion and engagement, an ironclad commitment to ensure equitable access 
and to leave no one behind, and multisectorality to address the social and structural 
determinants of health
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Population-focused service integration should be prioritised to address the needs of 
underserved populations. Adolescents of all genders and sexual orientations need 
adolescent-friendly information and services that are relevant, comprehensive, and address 
their sexual and HIV risks in a broader framework that is focused on their wellbeing, rights, 
and needs. Especially in settings where marginalised populations are not well served by 
mainstream health services, integration and co-location of services for these populations is 
urgently needed to enhance access to good-quality and culturally appropriate care and 
support. Notably in Russia and the wider eastern Europe and central Asian region, and any 
other setting where substantial injecting opioid use occurs, immediate efforts are needed to 
scale-up and integrate harm reduction services, overdose prevention, evidence-based drug 
treatment, and HIV, tuberculosis, and HCV services for people who inject drugs.
Efforts to integrate the HIV response more broadly into national health systems should be 
undertaken thoughtfully and follow careful study. Models should be used to predict the 
effects and cost-effectiveness of service integration scenarios.
Additional financing will be necessary to sharply reduce new HIV infections. Robust 
financing of the Global Fund and continuation of PEPFAR will be crucial to future prospects 
for reducing new HIV infections and AIDS-related deaths. Categorical HIV funding will 
remain essential for the foreseeable future and while transiting toward greater integration, 
although incremental steps should thoughtfully incorporate HIV funding over time into 
broader health insurance schemes. Innovative formulae to fund co-located, multidisease, and 
integrated services should be explored immediately.
No one must be left behind in the HIV response. All countries, including upper-middle-
income and high-income countries, must accept the responsibility to provide life-saving 
services for all segments of their population, but in cases where countries fail in this 
responsibility, strong and flexible international mechanisms must be available to fund 
community-based services for marginalised groups. The HIV response must take bolder 
action to remove social and structural barriers to good health; this includes dismantling the 
global war on drugs, repealing laws that criminalise same-sex relations, and eliminating laws 
that criminalise HIV exposure, non-disclosure, or transmission.
3. The HIV response must make common cause with the global health field to achieve 
sustainable health for all
Prioritised and sustained efforts are necessary to make health systems fit for the purpose of 
delivering sustainable and people-centred care. National governments, international donors, 
health professionals, and health advocates should work to create health systems that are 
capable of ensuring universal health access and managing multiple health problems 
simultaneously, with services tailored to the needs of individual patients. Major new 
investments by countries and by international donors will be essential and should focus on 
key elements of health systems, including strengthened primary care, medical education and 
training, laboratory systems, systems for procurement and supply management, and quality 
assurance and continual performance improvement. Health systems should be transformed 
to create user-friendly and outcome-oriented service delivery platforms for children, 
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adolescents, and men as well as for marginalised populations such as sexual minorities and 
people who inject drugs.
As an early step toward the long-term goal of integrating HIV and NCD services, existing 
HIV service platforms should be adapted to enable the delivery of co-located and integrated 
services for NCDs. HIV service providers must move beyond their singular focus on viral 
suppression as the goal of HIV care and treatment and recognise (through adapted training 
programmes, recon-figured clinics, and expanded monitoring and evaluation indicators) 
prevention and management of NCDs as core HIV outcomes.
High-level global dialogue that includes the private sector is urgently needed to mainstream 
a new paradigm for the development and provision of public goods. Drawing on experience 
from the HIV response, originator pharmaceutical companies should, as a standard practice, 
routinely enter into voluntary licenses for the full array of their product portfolios. Voluntary 
licenses for medicines and other public goods should maximise the coverage in LMICs 
using mechanisms such as sliding (ie, reasonable royalty payments to address differences 
among countries in ability to pay). The viability of a robust and flexible generics 
pharmaceutical industry must be preserved through, for example, the protection of 
flexibilities under international intellectual property agreements to ensure access to essential 
medicines and other public goods.
A review of global health governance architecture is needed. With the authorisation of a 
resolution of the UN General Assembly, a high-level, time-limited, and independent effort 
should be launched to develop a new global health governance architecture to catalyse and 
guide a new era of global health solidarity. As a subset of this review of global health 
governance, this independent exercise should generate concrete recommendations for HIV 
governance, with the goals of eliminating duplication, enhancing coherence, and refocusing 
global HIV governance on the overriding task of reviving global support and commitment 
for the HIV response. Mechanisms for global health governance must be democratic, 
inclusive, transparent, accountable, and grounded in a respect for human rights and gender 
equity, with specific steps that ensure the input and engagement of community, civil society, 
and other non-governmental actors.
The Commission recognises the urgent need to translate this vision of a new era of global 
health solidarity into a concrete action plan. The Commission will work to develop a clear, 
time-bound plan for implementing these recommendations in the coming year.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key messages
• The HIV pandemic is not on track to end, and the prevailing discourse on 
ending AIDS has bred a dangerous complacency and may have hastened the 
weakening of global resolve to combat HIV
• Existing HIV tools and strategies are insufficient, and although dramatic gains 
can be made through maximizing existing prevention and treatment strategies, 
the HIV pandemic is likely to remain a major global challenge for the 
foreseeable future
• Tens of millions of people will require sustained access to antiretroviral 
therapy for decades to come, vigilance will be needed to prevent a resurgence 
of the epidemic as the largest-ever generation of young people age into 
adolescence and young adulthood, and intensified efforts are required to 
address HIV among populations and settings that are being left behind
• Allowing the pandemic to rebound after achieving such remarkable progress 
would not only increase the human and financial costs of HIV, but it would 
potentially demoralise the global health field and diminish support for 
similarly ambitious global health undertakings
• A rejuvenated global effort on HIV is essential; to renew and strengthen the 
global HIV response, the world’s impressive commitment to the scaling up of 
HIV treatment services must be matched by a similarly robust commitment to 
expanded access to HIV prevention
• The HIV response must make common cause with the broader global health 
field to herald a new era of global solidarity for health, and specific action is 
urgently needed to respond to the rapidly rising health toll associated with 
non-communicable diseases, including taking health into account in the 
development of public policies of all kinds. HIV services should, where 
feasible, be integrated with broader health services, in co-located sites where 
possible, with the aim of improving both HIV-related and non-HIV-specific 
health outcomes; greater integration of HIV and global health must preserve 
and build on key attributes of the HIV response, including participatory 
community and civil society engagement and an ironclad commitment to 
human rights, gender equality, and equitable access to health and social 
justice
• The new era of global health solidarity should focus on the development of 
robust, flexible, people-centred health systems to end communicable diseases, 
develop effective measures to address the steady rise of non-communicable 
diseases, achieve universal health coverage, provide coordinated services 
tailored to the needs of health service users, and effectively address the social 
and structural determinants of health
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Panel 1:
Health targets for Sustainable Development Goal 3
• By 2030, reduce the global maternal mortality ratio to less than 70 deaths per 
100 000 livebirths
• By 2030, end preventable deaths of newborn babies and children younger 
than 5 years, with all countries aiming to reduce neonatal mortality to at least 
as low as 12 deaths per 1000 livebirths and under-5 mortality to at least as low 
as 25 deaths per 1000 livebirths
• By 2030, end the epidemics of AIDS, tuberculosis, malaria, and neglected 
tropical diseases and combat hepatitis, water-borne diseases, and other 
communicable diseases
• By 2030, reduce by a third premature mortality from non-communicable 
diseases through prevention and treatment, and promote mental health and 
wellbeing
• Strengthen the prevention and treatment of substance abuse, including 
narcotic drug abuse and harmful use of alcohol
• By 2020, halve the number of deaths and injuries from road traffic accidents 
globally
• By 2030, ensure universal access to sexual and reproductive health-care 
services, including for family planning, information, and education and 
ensure the integration of reproductive health into national strategies and 
programmes
• Achieve universal health coverage, including financial risk protection, access 
to quality and essential health-care services, and access to safe, effective, 
quality, and affordable essential medicines and vaccines for all
• By 2030, substantially reduce the number of deaths and illnesses from 
hazardous chemicals and air, water, and soil pollution and contamination
• Strengthen the implementation of the WHO Framework Convention on 
Tobacco Control in all countries, as appropriate
• Support the research and development of vaccines and medicines for the 
communicable and non-communicable diseases that primarily affect 
developing countries, provide access to affordable essential medicines and 
vaccines, in accordance with the Doha Declaration on the TRIPS Agreement 
and Public Health, which affirms the right of developing countries to use to 
the full the provisions in the Agreement on Trade-Related Aspects of 
Intellectual Property Rights regarding flexibilities to protect public health, 
and, in particular, provide access to medicines for all
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• Substantially increase health financing and the recruitment, development, 
training, and retention of the health workforce in developing countries, 
especially in least developed countries and small-island developing states
• Strengthen the capacity of all countries, in particular developing countries, for 
early warning, risk reduction, and management of national and global health 
risks
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Panel 2:
Longer-term opportunities to maximise synergies
Integrated care in mainstream health services
Key action items:
• Health systems strengthening interventions (eg, payment systems, patient 
incentives, procurement and supply management, workforce training, 
laboratory strengthening)
• Progressive integration of treatment services for HIV and non-communicable 
diseases
• Steps to ensure that all health services are adolescent-friendly
• Clinic and community interventions to increase men’s use of health-care 
facilities
• Capacitation of health systems to address the needs of marginalised 
populations, including sexual minorities and migrants
• Steady progress towards universal health coverage (with HIV progressively 
folded into broader health insurance schemes)
Addressing social and structural issues
Key action items:
• Repeal of criminalisation laws
• Multisectoral budgeting, planning, and accountability for results
• Following through on women’s equality and LGBTI agenda
• Steps to ensure an enabling environment
LGBTI=lesbian, gay, bisexual, transgender, and intersex.
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Panel 3:
Modelling HIV, diabetes, and hypertension screening in South Africa
Thembisa is an integrated demographic and HIV model developed for South Africa. The 
process of calibrating the model to data on HIV prevalence, HIV diagnosis, and mortality 
has previously been described.206,210 In this analysis, the prevalence of diabetes (defined 
as a concentration of HbA1c ≥6·5%) and hypertension (defined as systolic blood pressure 
≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or current use of blood pressure 
medication) was estimated from the age-specific and sex-specific prevalences measured 
in the 2012 South African National Health and Nutrition Examination Survey 
(SANHANES).205 Age-specific and sex-specific rates of diagnosis for diabetes and 
hypertension were estimated from the same source. The average annual proportion of the 
adult population (aged 15 years and older) screened was assumed to be to 10%.
208,209,211,212
 This average proportion was scaled by age-specific and sex-specific 
adjustment factors based on similar screening programmes in Uganda.209 Uptake of 
screening was assumed to be independent of disease status and further assumed to be 
constant over the period from July 1, 2018, to June 30, 2028. The proportion of newly-
diagnosed individuals who linked to care and started treatment soon after diagnosis was 
set to 40% in the case of HIV,213 45% in the case of diabetes, and 33% in the case of 
hypertension.210 A more detailed description of the model is provided in the appendix, as 
are sensitivity analyses with lower programme coverage and lower sensitivity and 
specificity of screening for hypertension and diabetes.
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Panel 4:
Modelling scenario for integrated screening for HIV, hypertension, and 
diabetes in Kenya
The Spectrum package was used to explore the potential effect of a country-wide 
campaign to integrate screening for HIV, diabetes, and hypertension.
Baseline ART coverage in 2016 was maintained at a fixed level from 2018 to 2028.
Following the framework of project SEARCH,146 we modelled a joint community-
outreach campaign for HIV and NCDs screening in the next decade (2018–28). We 
assumed that each year, a geographically distinct area of Kenya comprising 10% of the 
population would receive the programme, and that 90% of eligible adults aged 15 years 
or older would be successfully screened for HIV, diabetes, and hypertension.
To model the potential effect on HIV-related outcomes, we ambitiously assumed that this 
intervention could successfully initiate and retain 81% of newly diagnosed individuals on 
ART (ie, assuming a target level of 90% linkage and 90% engagement in HIV care after 
diagnosis). This corresponds to a 73% reduction in unmet need for ART in people living 
with HIV in the next decade, modelled as a linear increase in the ART coverage in each 
subgroup from 2018 to 2028.
Using a representative national survey,215 we estimated the proportion of adults with, 
aware of, and receiving medication for hypertension and diabetes. Based on the number 
of adults screened and the expected uptake of treatment, we estimated the effect of the 
integrated intervention on awareness of and treatment for hypertension and diabetes.
To assess cost-effectiveness, intervention costs were based on those reported in the 
SEARCH study,216 and the number of people receiving ART and HIV-related DALYs 
were obtained from Spectrum. As most treatment costs and DALYs are incurred later in 
life for NCDs, we report the change in discounted lifetime treatment costs and DALYs 
with and without intervention. These estimates are based on published treatment cost and 
DALY estimates,217 and are discounted at 3% per year. More details about the 
experimental scenarios are provided in the appendix.
Sensitivity analyses with less ambitious programme coverage (5% vs 10% of the national 
population per year), lower antiretroviral therapy uptake, and lower sensitivity and 
specificity of screening for hypertension and diabetes are also presented in the appendix.
NCD=non-communicable disease. ART=antiretroviral therapy. DALYs=disability-
adjusted life-years.
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Panel 5:
Modelling scenario for integration of HIV and reproductive health services 
in Nigeria
Spectrum’s demproj, AIM/GOALs, and FamPlan modules were used to create three 
scenarios describing integration of HIV and reproductive health services in Nigeria.
At baseline, the 2016 PMTCT coverage (about 26% of HIV-positive pregnant women) 
and contraceptive use prevalence (15%) were maintained at fixed levels from 2018 
through 2028. We further modelled the transition away from PMTCT Option B 
(provision of ART during pregnancy and breastfeeding) by year 2020, and replaced that 
with an equal coverage through Option B+ programmes (providing lifelong ART for all 
pregnant women living with HIV).
For family planning, the prevalence of contraceptive use was scaled up linearly from 15% 
in 2018, to 31% in 2023 (to meet the unmet need for contraceptives by married Nigerian 
women),220 and was maintained at that fixed level until 2028.
For PMTCT, the proportion of HIV-positive pregnant women receiving ART through 
Option B+ was scaled up linearly from 16% in 2016, to an ambitious target of 90% 
coverage in 2023 (in accordance to UNAIDS and PEPFAR targets) for 95% PMTCT 
coverage221 and was maintained at that target level until 2028.
For combined PMTCT and family planning, starting in 2018, both PMTCT coverage and 
contraceptive use were scaled up linearly as described for each individual scenario above.
To assess cost-effectiveness, PMTCT costs were based on PEPFAR estimates.222 HIV-
related treatment costs and DALYs were estimated as described for Kenya (panel 4). The 
effects of increased family planning access were estimated using the Impact Now model.
223
 Family planning costs were based on a person-year cost of US$3·48 for a mix of 
contraceptive methods. Per-user family planning costs ($3·48), maternal and infant 
health-care costs averted ($3·15), and DALYs averted (0·35) were derived from the 
ImpactNow model.
PMTCT=prevention of mother-to-child-transmission. ART=antiretroviral therapy. 
DALYs=disability-adjusted life-years.
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Panel 6:
Modelling scenario for the integration of HIV and sexually transmitted 
infections in India: MSM and FSW
The Spectrum package was used to model HIV transmission in MSM and FSM in India. 
An intervention scenario was modelled to represent integration of services for HIV and 
sexually transmitted infections for these populations.
At baseline, ART coverage was maintained at the estimated 2016 level from 2018 to 
2028.
Using data from the Avahan programme, we modelled a joint community-outreach 
campaign for HIV and sexually transmitted infection screening in MSM over a 5-year 
period (2018–23). On the basis of reported levels of population coverage from Avahan, 
we assumed that this programme could reach 60% of MSM and 90% of FSM and will 
provide an infrastructure for maintaining all improvements in HIV treatment and PrEP 
coverage over the subsequent 5 years (2024–28). To model the potential effect on HIV-
related outcomes, we assumed that this integrated intervention can successfully deliver 
ART to 81% of individuals with diagnosed HIV who are not currently receiving HIV 
treatment (ie, 90% linkage and 90% engagement). This corresponds to a 54% and 81% 
reduction in the unmet need for ART in HIV-positive MSM and FSM, respectively. We 
modelled this effect as a linear increase in the rate of ART coverage from 2018 to 2023. 
Furthermore, to estimate the potential effect of PrEP, we modelled two additional 
scenarios for implementation of oral PrEP in these two populations at low (10%) and 
high (30%) levels of coverage. In these scenarios, PrEP coverage was increased linearly 
from 2018 to 2023 (continuing at fixed levels through 2028), and PrEP adherence was 
assumed at 50% for those individuals on PrEP.
Because of a lack of representative data on the incidence and prevalence of sexually 
transmitted infections in these two populations, we limited our analysis to study the effect 
of integrated programmes for screening and treating syphilis infection. Moreover, 
because of the complexity of modelling the co-epidemics of syphilis and HIV infections 
in India, we chose a simplified approach for estimating the effect of the intervention on 
programme participants only and did not estimate the effect on secondary infections 
averted. Using an array of available estimates from the scientific literature, we estimated 
the national prevalence of syphilis at 5·8% of FSW and 3·5% of MSM (appendix).
Following the methodology proposed by Solomon and colleagues,227 we modelled a 
scenario for reaching these two populations through respondent-driven sampling, 
whereby members of these populations are incentivised to visit programme sites and refer 
others to programme sites, at an estimated cost of US$20·33 per person tested. ART costs 
were estimated at $126·06 per person-year. PrEP costs of $91 per person-year were based 
on Stover,228 with updated drug cost estimates for tenofovir disoproxil fumarate plus 
lamivudine.229 Syphilis testing and treatment costs for FSW and MSM were estimated at 
$3·50 and $9·30, respectively.230 DALYs per prevalent syphilis case (0·64) were 
calculated using the method by Korenromp and colleague,230 using estimates of the 
global DALYs for syphilis231 and the global prevalence of syphilis.232
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MSM=men who have sex with men. FSW=female sex workers. ART=antiretroviral 
therapy. PrEP=pre-exposure prophylaxis. DALYs=disability-adjusted life-years.
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Panel 7:
Modelling methods: integrated harm reduction and ART in Russia
We used a dynamic epidemic model of HIV in people who inject drugs to assess the 
potential effect of integrated harm reduction and HIV services for this population in 
Russia. Full methodological details are in the appendix.
A dynamic and deterministic model of HIV transmission in this population was 
developed, incorporating injecting and sexual transmission in people who inject drugs. 
People who inject drugs enter due to injecting initiation and exit due to cessation of 
injecting or death (overdose, HIV-related death, or non-HIV background mortality). The 
model was stratified by HIV disease stage (uninfected, acute, latent, pre-AIDS, AIDS), 
ART status, risk (low or high, defined as history of incarceration on the basis of survey 
data for both settings), sex, and harm reduction access (off or on). We assumed no 
baseline coverage of any harm reduction and minimal ART coverage (26% of HIV-
infected people who inject drugs in 2014). We modelled harm reduction scale-up through 
exploring different scenarios of harm reduction programme availability: high coverage 
NSP only, non-naltrexone MAT only, or combined NSP and MAT service, either alone or 
integrated with expanded ART for people who inject drugs. NSP and non-naltrexone 
MAT were assumed to reduce injecting-related HIV transmission risk.
Non-naltrexone MAT was additionally assumed to increase ART recruitment rates, 
reduce treatment drop-out, and reduce rates of fatal overdose. However, we also 
incorporated increased mortality risk within the first 4 weeks of MAT initiation and 
discontinuation. ART was assumed to reduce HIV-related mortality, as well as sexual and 
injection-related transmission.
The model was calibrated to two cities with differing epidemic profiles in Russia: Omsk 
(high but expanding HIV epidemic in people who inject drugs) and Ekaterinburg (very 
high but stable HIV epidemic). For each setting, the model was calibrated to multiple 
timepoints of HIV prevalence in people who inject drugs, stratified by sex and risk 
(incarceration history, when available), ART coverage in 2014, proportion high risk (ever 
incarcerated), and the estimated proportion of transmission related to sexual risk. Because 
of uncertainty, most parameters were sampled from underlying distributions, generating 
100 parameter sets. For each parameter set, the model was calibrated to the data using an 
optimisation solver and minimising the sum log likelihood. For each of these 100 
calibrated parameter sets, model scenarios were run and projections presented as means 
and 2·5–97·5% intervals.
We examined the effect of the following intervention scale-up scenarios: (1) no harm 
reduction base-case; (2) NSP for 50% of people who inject drugs; (3) MAT for 25% of 
people who inject drugs; (4) MAT for 50% of people who inject drugs; (5) combination 
NSP-MAT for 50% of people who inject drugs; and (6) combination NSP-MAT for 50% 
of people who inject drugs integrated with scaled-up ART for HIV-infected people who 
inject drugs on harm reduction (recruited at three times current rates). We tracked the 
effect on HIV infections and fatal overdoses in people who inject drugs.
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The percentage of new HIV infections and fatal overdoses in people who inject drugs 
averted in the next decade was calculated by comparing the cumulative projected number 
of events from 2018 to 2028 with intervention scale-up compared with the base-case.
ART=antiretroviral therapy. NSP=provision of clean needles and syringes. 
MAT=medication-assisted therapy. HCV=hepatitis C virus.
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Figure 1: Ten leading causes of death in 2015
(A) Low-income economies. (B) Low-middle-income economies. (C) Upper-middle-income 
economies. (D) High-income economies. Source: WHO.
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Figure 2: Life expectancy in 2000 and 2016
Source: WHO
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Figure 3: Global burden of hepatitis B virus and hepatitis C virus
(A) Prevalence of hepatitis B virus infection between 1957 and 2013. (B) Prevalence of anti-
hepatitis C virus between 1990 and 2013. Adapted from Schweitzer et al (2015)49 and from 
Gower et al (2014),50 by permission of Elsevier.
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Figure 4: Knowledge of HIV status, treatment coverage, and viral load suppression by region in 
2016
Comparison of HIV testing and treatment cascades by region reveals different patterns of 
progress. Western and central Europe and North America are approaching global targets. 
Latin America and eastern and southern Africa show high levels of achievement across the 
cascade. Eastern Europe and central Asia, the Middle East and North Africa, and western 
and central Africa are clearly off track. Source: UNAIDS special analysis, 2017.
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Figure 5: African American men who have sex with men have an increased lifetime acquisition 
probability of HIV infection in 2018
Credit: © NASTAD.
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Figure 6: Activism on HIV in India
Students recognise International AIDS Candlelight Memorial Day with painted faces at the 
Centre for Social Work, Panjab University, Chandigarh, India. Credit: © 2016 Gaurav Gaur, 
Photoshare.
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Figure 7: Sexual and emotional health in adolescents in India
A young girl attends a candlelit march for sexual and emotional health for young teens in 
Udaipur, India. Credit: © 2016 Arvind Jodha/UNFPA, Photoshare.
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Figure 8: HIV testing, family planning education and referrals, and deworming kits in Uganda
A dance troupe with Public Health Ambassadors Uganda perform in the Kasana Market in 
Luwero to call attention to a pop-up health clinic providing HIV testing, family planning 
education and referrals, and deworming kits.
Credit: © 2016 David Alexander, Photoshare.
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Figure 9: HIV testing services in Kenya
A counsellor provides HIV testing services to livestock herders during community outreach 
services in the Eremit area of Kajiado County, Kenya. Credit: © 2012 George N Obanyi/FHI 
360, Photoshare.
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Figure 10: Prevention of mother-to-child transmission of HIV in Nigeria
Mothers and children in Alausa Area of Lagos, Nigeria, during a state-sponsored 
educational programme on prevention of mother-to-child transmission of HIV. Credit: © 
2014 Kunle Ajayi, Photoshare.
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Figure 11: Monitoring babies for signs of congenital Zika syndrome in Honduras
At Tela Hospital in El Progreso City, Honduras, Ileana Mayes Flores, the only geneticist in 
the public sector of Honduras, examines Aylin Meja, a baby aged 3 months whose mother, 
Sandra Meja aged 19 years, was infected with the Zika virus during pregnancy. The medical 
staff is closely monitoring her baby for signs of congenital Zika syndrome. Credit: © 2017 
Brendan Bannon/USAID, Photoshare.
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Figure 12: Patients undergo drug detoxification while handcuffed to their beds at a programme 
for heroin addiction in Ekaterinburg, Russia
Credit: Brendan Hoffman.
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Figure 13: A multicountry modelling exercise to study the effect of HIV integration in various 
settings
NCDs=non-communicable diseases. MSM=men who have sex with men. FSW=female sex 
workers. ART=antiretroviral therapy.
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Figure 14: South African health statistics and the potential effects of multidisease screening
(A) HIV estimates are obtained from the Thembisa model estimates for 2016, whereas 
diabetes and hypertension estimates are from the 2012 South African National Health and 
Nutrition Examination Survey. Controlled on treatment is defined in the case of HIV as 
having a viral load less than 400 copies per mL, and in the case of diabetes as a HbA1c 
concentration less than 7%. Estimates of treatment coverage and control rates among 
hypertension cases are obtained from a national survey in 2010. (B) The expected fraction of 
screened individuals testing positive, the expected fraction of newly diagnosed individuals, 
and the expected fraction of individuals linking to treatment services in the context of a 
multidisease screening programme implemented between 2018 and 2028.
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Figure 15: Differented care in South Africa—The Tutu Tester mobile screening programme for 
HIV, tuberculosis, diabetes, hyptertension, and body-mass index
Credit: Desmond Tutu HIV Research Foundation/Alexis Dominguez
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Figure 16: Projected effects of HIV and NCD integration scenarios in Kenya
(A-B) The projected effect of the intervention on the number of new HIV infections and 
AIDS deaths in Kenya in the next decade (2018–28). (A) Effects of the care cascade in 
intervention communities in 2018, and similar patterns of improvement in cascades are 
expected for each new set of intervention communities. (B) Improvements in care cascades 
in 2018 averaged for the whole country. National care cascades are expected to continue to 
improve through the end of programme in 2028. (C-D) The care cascades for HIV, 
hypertension, and diabetes in adults before and after first year (2018) of implementation in 
intervention communities and in Kenya, respectively. Intervention communities constitute 
representative 10% of the adult population (aged ≥15 years), with assumption of 90% 
screening uptake and treatment uptake after diagnosis of 81% for HIV, 23% for 
hypertension, and 45% for diabetes. NCD=non-communicable disease. ART=antiretroviral 
therapy.
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Figure 17: Projected effects of HIV and reproductive health services integration scenarios in 
Nigeria
(A) Total fertility rate. (B) Number of unintended pregnancies averted. (C) Number of 
infants infected with HIV. (D) Cumulative number of new HIV infections in Nigeria. 
Scenarios include expansion of family planning services by increasing the prevalence of 
contraceptive use from 16% at baseline to 31% in 2023, and expansion of PMTCT by 
increasing the coverage to reach 90% of HIV-positive pregnant women in Nigeria by year 
2023, compared against baseline levels in Nigeria. PMTCT=prevention of mother-to-child 
transmission.
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Figure 18: Projected effects of HIV and sexually transmitted infection services integration 
scenarios for MSM and FSW in India
The number of new HIV infections in (A) MSM and (B) FSW. Intervention scenarios 
include expansion of ART coverage in MSM (from 43% to 73%) and FSW (from 29% to 
81%) with no PrEP, at a low PrEP coverage of 10%, and at a high PrEP coverage of 30%. 
Each scenario is modelled as a gradual increase in coverage of ART and PrEP in MSM and 
FSW from 2018 to 2023, continued at a fixed coverage afterward (2024 to 2028). 
MSM=men who have sex with men. FSW=female sex workers. PrEP=pre-exposure 
prophylaxis. STI=sexually transmitted infections.
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Figure 19: Model projections of the effect of integrated harm reduction and HIV services in two 
Russian cities
Model projections of (A) median HIV prevalence in PWID in Omsk, Russia, (B) median 
HIV prevalence in PWID in Ekaterinburg, Russia, (C) proportion HIV infections averted in 
PWID in 2018–28, and (D) proportion of fatal overdoses averted in PWID in 2018–28 with 
various levels of intervention scale-up. Scenarios include no harm reduction or ART (base 
case), expansion of NSPs to 50% coverage in PWID (NSP 50%), expansion of MAT to 25% 
or 50% of PWID (MAT 25%; MAT 50%), combination MAT and NSP to 50% of PWID 
(MAT+NSP 50%), or combination MAT and NSP to 50% of PWID integrated with ART 
recruited at three times the base-case recruitment rate of HIV-infected PWID on harm 
reduction per year from 2018. Observed HIV prevalence data in PWID shown as black 
circles and 95% CI; dashed lines are 2·5–97% uncertainty bounds. Box plots indicate the 
median (middle line) projections, 25–75% percentile range (boxes), and 2·5–97·5% 
percentile range (whiskers), and median estimates reported above box plots. PWID=people 
who inject drugs. ART=antiretroviral therapy. MAT=medication-assisted therapy. 
NSP=needle and syringe programme.
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Figure 20: Community-led prevention providing combination prevention including pre-exposure 
prophylaxis to their peers in Thailand
Credit: © Richard Nyberg, USAID.
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Table:
Immediate opportunities for synergies through co-located services, by service platform
Population (or populations)
Co-located HIV and SRHR services Women, adolescent girls, sexual minorities
Co-located HIV and antenatal services Pregnant women
Co-located HIV and paediatric health services Children living with HIV
Co-located and jointly planned HIV and tuberculosis screening and 
treatment services
People with or at risk of HIV-tuberculosis co-infection
Co-located HIV and HCV screening and treatment services People with or at risk of HIV-HCV co-infection
Co-located drug treatment or rehabilitation for HIV, NSP, and MAT People who inject drugs
Screening for HIV and NCDs General population in high-burden settings
Management of NCDs in HIV service platforms People living with HIV and people with or at high risk of NCDs
SRHR=sexual and reproductive health and rights. HCV=hepatitis C virus. NSP=provision of clean needles and syringes.MAT=medication-assisted 
therapy. NCDs=non-communicable diseases.
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